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ABSTRACT
This study examines the transcriptional differences between nerve wounds treated with silicone
tubes and those treated with collagen nerve regeneration templates. The primary motivation for
the study is to test the hypothesis that the discrepancy between the low-quality regenerate that
forms in a silicone tube and the high-quality regenerate that forms in a collagen tube is due to
differences in gene transcription. We used in vivo experiments on rat sciatic nerves with the use
of real-time PCR to study the mRNA expression levels of certain inflammatory cytokines and
contractile proteins after injury in both silicone-treated and collagen-treated nerve wounds. The
contents of the wound site were analyzed on days 1, 3, 7, 14, and 21 following injury. The
results of this experiment showed that although a difference in mRNA expression of a-SM actin
is significantly higher at later time points in silicone-treated wounded nerves as compared to
collagen-treated wounded nerves, there is little or no significant difference in the mRNA
expression of TGF-P 1, TGF-P2, and TGF-P3 in wounds from the two devices. This suggests that
the presence of a collagen regeneration nerve template does not direct the wound healing process
at a transcriptional level.
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Chapter 1: Introduction
The emerging field of tissue and organ regeneration has the potential to profoundly affect
the scientific and medical communities with many applications that can greatly improve quality
of life. Currently, a great deal of research is being done on developing methods to improve the
quality of tissue regeneration and prevent the normal adult wound healing response of
contraction and scar formation that normally leads to wound closure. One such method makes
use of collagen scaffolds and has been shown to have significant success in regenerating skin,
peripheral nerves as well as the conjunctiva. Nevertheless, the underlying mechanism by which
regeneration, rather than contraction and scar formation, occurs in a wound is not completely
understood.
This study aims to begin to fill in some of the gaps in understanding the mechanism of
induced regeneration using collagen scaffolds. By identifying critical differences in the body's
response to nerve wounds treated with two devices that lead to quite different outcomes, namely,
collagen tubes and silicone tubes, we hope to identify the key reasons why collagen scaffolds
produce a much higher quality nerve regenerate. In particular, this study compares the mRNA
expression levels of several proteins (fibronectin, TGF-P1, TGF-P2, TGF-P3, and a-SM actin), in
both silicone-treated nerve wounds and collagen-treated nerve wounds. There is significant
evidence in the literature that these proteins play key roles in the wound healing process.
Determining whether there is a difference in the wound healing response at the
transcriptional level between collagen-treated nerves and silicone-treated nerves will begin to
give us an understanding of what the underlying mechanism that leads to high quality tissue and
organ regeneration consists of. Ultimately, understanding the mechanism by which the body can
be induced to regenerate tissue will allow us to more efficiently research new techniques and
methods of inducing regeneration as well as design devices and procedures that can have
practical applications in the medical field.
Chapter 2: Background
2.1 Wound Healing
The body's response to injury is a complicated process that involves multiple stages and
varies according to the type of tissue as well as the physical and chemical environment
surrounding the wound. Previous studies have shown that the human body's response to injury
changes during the late stage of fetal development (Yannas 2005). The early fetus' response to
wounding primarily involves regeneration of tissue (Colwell, Longaker et al. 2005) while the late
fetal to adult response involves a greater amount of contraction and scar formation (Ramirez,
Soroff et al. 1969; Yannas 2001). These two quite distinct healing processes will be reviewed
briefly below.
2.1.1 Early Fetal Wound Healing Response
The early fetal stage refers to the first two trimesters of gestation in mammals. Early
fetal wound healing is characterized by tissue regeneration rather than the adult processes of
wound closure, i.e., contraction and scar formation. In early mammalian fetal wounds in skin
and other organs, complete scarless healing can be spontaneously achieved. One of the most
important features of such scarless healing is that it lacks an acute inflammatory response (Clark
and Henson 1988; Martin 1997; Colwell, Longaker et al. 2005). Early fetal platelets release a
much smaller amount of inflammatory cytokines (Olutoye, Yager et al. 1996), and despite being
very similar in structure to adult platelets, early fetal platelets tend not to aggregate when
exposed to collagen (Olutoye, Barone et al. 1997). Finally, hyaluronic acid, which is present in
high concentrations in early fetal skin wounds, serves to suppress aggregation of platelets and
release of platelet derived growth factor (PDGF), a process associated with platelet aggregation
and white thrombus formation in adults (Olutoye, Barone et al. 1997). Consequently, early fetal
wound healing, especially in skin, has become a major subject of study and has become the
standard of ideal wound healing in mammals.
2.1.2 Late Fetal & Adult Wound Healing Response
Toward the end of the second trimester of gestation in mammals, the fetus undergoes a
drastic change in its wound healing response and retains this new method of wound healing
throughout adulthood. In contrast to the early fetus, late fetal and adult wound healing is
characterized by wound contraction and scar formation rather than tissue regeneration.
Wound contraction is generally attributed to particular cells called contractile fibroblasts,
or myofibroblasts. Fibroblasts, which are normally present in the body and are responsible for
synthesizing connective tissue, typically undergo differentiation into myofibroblasts at wound
sites. These myofibroblasts behave much like smooth muscle cells and contract the surrounding
tissue (Darby and Hewitson 2007). They have been shown to generate contractile forces in adult
skin wounds (Cohen, Diegelmann et al. 1992; Gabbiani 1998) as well as in nerve wounds
(Chamberlain, Yannas et al. 1998; Chamberlain, Yannas et al. 2000). Depending on the species,
the fraction of a wound that closes by contraction can range anywhere from 95 percent to 35
percent in the late fetus or early adult skin, 95 percent in peripheral nerves, and 45 percent in the
conjunctiva. In skin wounds, the differences between species has often been attributed to the
variations in how anchored the skin is to the underlying muscle tissue (Yannas 2001).
Scar formation comprises the other main component of late fetal and adult wound
healing. Scar tissue typically differs from native tissue in a variety of ways. In skin, scar is
normally much less extensible but is mechanically weaker than normal dermal tissue (Dunn,
Silver et al. 1985). It also is characterized by highly oriented connective tissue fibers, while the
connective tissue in native dermis tends to be randomly oriented (Gibson, Kenedi et al. 1965;
Dawber and Shuster 1971; Brown 1972; Holbrook, Byers et al. 1982; Ferdman and Yannas
1993). Lastly, scar is much less vascularized and generally lacks the appendages of the dermis
such as sweat glands and hair follicles (Martin 1997). Similarly, in a transected nerve, the caps
that form at the tips of a neuroma manifest many characteristics of scar tissue. While native
nerve tissue contains many highly organized bundles of axons, the tissue caps of neuroma
contain mostly disorganized connective tissue that is poorly vascularized and has tangles of few
small diameter axons (Wall and Gutnick 1974; Olsson 1990; Sunderland 1990; Zochodne and
Nguyen 1997; Chamberlain, Yannas et al. 2000).
Thus, in stark contrast to the regeneration of tissue seen in the early mammalian fetus, the
late fetal and adult response to injury consists of a combination of wound contraction and scar
formation to close and subsequently fill the defect space.
2.2 Induced Organ Regeneration
Despite the differences in wound healing response between the early fetus and the late
fetus and adult, however, prior research has suggested that the late fetal and adult body may
retain some of the regenerative capacity demonstrated by the early fetus. Under proper
conditions, the late fetal and adult bodies have demonstrated a wound healing response similar to
that of the early fetus, which involves a much greater amount of tissue regeneration with
significantly less contraction and scar formation (Yannas 2005).
2.2.1 Induced Skin Regeneration
Many of the early studies of tissue regeneration focused on skin wounds. Skin tissue is
comprised of three distinct layers: epidermis is the relatively thin outer layer of the skin, dermis
is the thicker layer of flesh that lies beneath the epidermis, and lastly the basement membrane is
the very thin layer which anchors the epidermis to the dermis. The dermis, or stroma layer, does
not naturally regenerate in an adult when injured; instead, it contracts and forms scar tissue.
Epidermis and basement membrane, however, regenerate spontaneously in adults when a layer of
dermis is present (Yannas 2001).
Proposed treatments for induced skin regeneration have included the use of growth
factors and other chemicals, sheets of epidermal cell culture, and unseeded and cell-seeded
collagen scaffolds or other degradable biosynthetic medium. For the purposes of skin tissue
regeneration, the most successful method has been the use of a collagen scaffold otherwise
referred to as a dermis regeneration template (DRT). In previous studies, the simplest conditions
for dermal regeneration include the use of a DRT alone while the simplest conditions for
simultaneous regeneration of dermis, epidermis, and basement membrane required the use of a
DRT seeded with keratinocytes (Yannas 2001).
In order to effectively induce regeneration, dermis regeneration templates need to adhere
to certain guidelines regarding degradation rate, average pore size, and chemical composition
(Yannas, Lee et al. 1989). It was found that the DRT played a key role in blocking wound
contraction and thus, the DRT had to remain undegraded until the contractile response had
finished. On the other hand, in order to allow regeneration, the DRT needed to degrade quickly
enough to allow the regenerating tissue to form. In the guinea pig model, for example, the
optimal half-life for the DRT was found to be between five and fifteen days. Meanwhile, the
average pore diameter also played a significant role in the efficacy of the DRT. The optimal
average pore diameter was found to be in the range 20 to 120pm (Yannas Iv, Jf et al. 1982). In
this case, the pores must be large enough to allow cells to infiltrate the DRT but small enough so
that the specific surface is large enough for all or most of the cells to find it possible to anchor on
the surface (Yannas 2001).
The mechanism by which the DRT induces partial skin regeneration has been proposed to
include a number of steps. The total number of cells and the ratio of cells demonstrating a
contractile phenotype to total number of cells in wounds treated with DRT were much lower than
untreated skin wounds (Murphy, Orgill et al. 1990; Troxel 1994). Also, the lack of banding on
the collagen in the DRT causes platelets to adhere but not aggregate when they come in contact
with the surface of the DRT (Yannas, Burke et al. 1975; Sylvester, Yannas et al. 1989; Yannas
1990). Contraction is delayed significantly in DRT treated skin wounds as compared to
untreated skin wounds. The onset of contraction in a guinea pig was delayed by five days due to
the use of DRT treatment and the contraction half-life was delayed by almost twenty days
(Yannas, Lee et al. 1989; Troxel 1994). As a consequence of the blocking of contraction by the
DRT, the plane stress field in the skin wound is cancelled out, leading to the synthesis of
randomly oriented collagen fibers in the defect site (Yannas 2001).
The result of these experiments is the capacity to produce partial skin regeneration. The
resultant tissue contains a well vascularized tissue structure comprised of loosely packed and
randomly oriented collagen fibers (Yannas, Burke et al. 1981; Yannas, Burke et al. 1982; Yannas
Iv, Jf et al. 1982). In this manner, the dermis, basement membrane, and epidermis can all be
regenerated by the use of a DRT; however, the resulting skin still lacks appendages such as hair
follicles and sweat glands.
2.2.2 Induced Nerve Regeneration
Induced regeneration of peripheral nerves has also been studied. Nerve tissue can be
divided into conducting tissue, which consists of actual neurons, and non-conducting tissue,
which comprises most of the ECM of the nerve. Neurons, which comprise the conducting tissue
of nerves, each possess an axon or cell process which connects the cell body to its sensory or
motor target.
Some axons are myelinated in which case the axon is encased by several layers of cytoplasm of a
surrounding Schwann cell (Figure 2.la). Unmyelinated axons do not have a myelin sheath, and
in such cases, a single Schwann cell encases many axons (Figure 2.1b).
Figure 2.1 (a) Diagram depicting the structure of a myelinated axon and (b) an unmyelinated
axon (Chamberlain 1998).
The non-conducting tissue is connective tissue whose function is to support and protect the
connective nerve tissue. The non-conducting connective tissue is comprised of the endoneurium,
perineurium, and epineurium (Figure 2.2).
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Figure 2.2 Schematic of a nerve trunk containing fascicles of neural fibers. The different types
of connective tissue (endoneurium, perineurium, and epineurium) are labeled (Chamberlain
1998).
The endoneurium, which consists of fibroblasts and loosely packed type III collagen surrounds
individual axons and their associated Schwann cells (Rosen, Hentz et al. 1983; Madison,
Archibald et al. 1992). Its primary function is to fill the space between nerve fibers (Thomas and
Olsson 1984) and to support the individual axons (Rosen, Hentz et al. 1983). The nerve fibers
are further organized into bundles called fascicles, which are surrounded by the perineurium.
The perineurium is formed from three concentric layers that envelope the fascicles, give the
nerve an elastic property, and act as a diffusion barrier (Sunderland 1990). Lastly, the
epineurium, which consists of a loose matrix of type I collagen fibers and fibroblasts (Rosen,
Hentz et al. 1983), holds the fascicles together and provides cushioning and protection for the
nerve against physical trauma and stress (Madison, Archibald et al. 1992; Chamberlain 1998).
After transaction of a nerve, regeneration requires the survival of neuron cell bodies, the
growth of axons across the injury site and reconnection of these axons with their appropriate
targets (Madison, Archibald et al. 1992). Similar to the DRT, an ECM analog referred to as the
nerve regeneration template (NRT) has been developed for the purposes of inducing regeneration
of peripheral nervous tissue (Chang, Yannas et al. 1990; Yannas 1995). In a common animal
model, the nerve ends of a transected sciatic nerve in the rat are placed inside a silicone or
collagen tube with a 10mm gap in between (Chamberlain 1998). Various studies involving
silicone and collagen tubes have demonstrated the ability to form perineurial connective tissue as
well as functional reconnection of axons through the use of these tubular nerve regeneration
templates (Azzam, Zalewski et al. 1991; Chamberlain, Yannas et al. 2000; Yannas 2001).
In typical studies of nerve regeneration using a silicone tube with a 10mm gap length,
much better regeneration was achieved than when no tube was used or when only one nerve end
was placed into the tube (Lundborg, Dahlin et al. 1982; Williams, Powell et al. 1984;
Chamberlain, Yannas et al. 2000). Regeneration generally begins with the formation of a fibrin
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cable that runs the gamut of the gap (Williams, Longo et al. 1983; Williams, Danielsen et al.
1987). Eventually, this cable is replaced by Schwann cells, fibroblasts, endothelial cells, and
myelinated axons, and a functional nerve trunk is formed (Williams, Longo et al. 1983; Williams
and Varon 1985; Yannas 2001). Another observation of these silicone studies is the formation of
a contractile capsule around nerve stumps and the regenerated nerve trunk (Lundborg, Dahlin et
al. 1982; Williams, Longo et al. 1983; Yannas, Orgill et al. 1987; Azzam, Zalewski et al. 1991;
Itoh, Takakuda et al. 1999; Chamberlain, Yannas et al. 2000). This thick (up to 15 to 20 cell
layers thick) sheath that encompasses the entire regenerated nerve trunk or the ends of the nerves
in a neuroma was identified to consist of contractile myofibroblasts (Chamberlain, Yannas et al.
2000). Meanwhile, this sheath was almost non-existent when the nerve wound was treated with
a collagen tube. Similar to the DRT, it was observed in collagen tubes that the myofibroblasts
had migrated into the pores of the scaffold (Chamberlain, Yannas et al. 1998; Chamberlain,
Yannas et al. 2000). These findings led to the development of the pressure cuff hypothesis
(Yannas 2001), which states that the contractile cells exert a circumferential force that leads to
closure of the nerve stumps unless otherwise opposed.
2.3 Roles of Specific Proteins in Organ Regeneration
While macroscopic observations concerning wound healing provide us with knowledge
about how the body responds to injury at the tissue level, another key to the entire process is the
interactions of biomolecules and the effects they have on cells and tissue as well as on extra
cellular matrix synthesis. In general, cytokines are chemical cellular signals which enable cells
to send each other messages (Xu and Clark 2000) that may up-regulate or inhibit cell
proliferation or cell activity and can even induce differentiation into certain types of phenotypes
(Yannas 2001). Specifically with regard to the body's response to injury, various growth factors
and proteins have demonstrated an indicatory or active role during the healing process (Mustoe,
Pierce et al. 1991; Pierce, Tarpley et al. 1992).
2.3.1 Fibronectin
The first protein of note that is present in wound healing is fibronectin. After injury, a
fibrin-fibronectin clot forms at the site of injury. This network of fibrils serves as a provisional
matrix and is the framework on which fibroblasts and other cells migrate and invade the wound
site (Hynes 1986). Fibronectin is an important element because of the cell adhesive complex that
resides on the molecule and allows cells to migrate into the wound site (McDonald 1992).
Eventually the fibrin-fibronectin clot is replaced by collagen and other more permanent structural
molecules including various proteins and connective tissue. Recently, differences in the effects
of fibronectin mRNA splicing have been observed between early fetal wound healing and late
fetal to adult wound healing. Fetal wounds express little to no change in spliced fibronectin
variant expression while late fetal and adult wounds have shown up-regulation of spliced
fibronectin variants, especially fibronectin-EDA (Li-Korotky, Hebda et al. 2007).
2.3.2 Transforming Growth Factor-beta 1
Transforming Growth Factor-beta 1 (TGF-Pj) has been identified as a key cytokine
involved in the differentiation of fibroblasts into myofibroblasts, which have a highly contractile
phenotype and are responsible for contraction at wound sites (Desmouliere and Gabbiani 1996;
Gabbiani 1998). TGF-31 is released from platelets during aggregation at a wound site, and
therefore, is readily present during injury. In vitro studies have shown that TGF-P1 caused a
dose-dependent increase in the contractile force of myofibroblasts (Bertoldo, D'Agruma et al.
2000). These studies are supported by fetal studies in which exogenous addition of TGF-P 1
caused dose-proportional scarring and fibrotic healing in fetuses (Sullivan, Lorenz et al. 1995;
Lanning, Nwomeh et al. 1999). Similarly, in vivo studies have shown that the addition of
neutralizing antibodies to TGF-P1 and TGF-12 have led to decreased scarring in late fetal
wounds (Shah, Foreman et al. 1995).
2.3.3 Transforming Growth Factor-beta 2
Like TGF-P31, transforming growth factor-beta 2 (TGF-P2) is associated with the
contraction and scar formation of the late fetal and adult wound healing response. Although the
actual role of TGF-12 in contraction and scar formation is not as well known as for TGF-P 1, the
in vivo studies involving exogenous addition of TGF-P2 or the addition of TGF-P2 blocking
antibodies to wound sites paralleled the findings of TGF-P31 (Shah, Foreman et al. 1995;
Sullivan, Lorenz et al. 1995; Lanning, Nwomeh et al. 1999).
2.3.4 Transforming Growth Factor-beta 3
Last of the three TGF-3 isoforms is transforming growth factor-beta 3 (TGF-P3), which
has been found to have an antagonistic role to TGF-P1 and TGF-32. In studies in which TGF-33
has been exogenously added to a wound site in an adult or late fetus, the amount of scarring
decreased (Shah, Foreman et al. 1995). Another study tracked the expression of all three TGF-[
isoforms throughout the wound healing process in both early fetuses and late fetuses. The
findings indicated that in early fetuses, TGF-P31 expression was lower than in later fetuses, and
the cytokine was cleared from the wound site much quicker. In contrast, TGF-P3 had an
increased expression and remained for a prolonged period of time. On the other hand, in late
fetuses, TGF-31 and TGF-P2 were present at higher levels and remained for a much longer
duration while TGF-P3 had a decreased expression and did not appear until much later in the
wound healing process (Soo, Beanes et al. 2003).
2.3.5 alpha-Smooth Muscle Actin
The final protein of note in this study is alpha-smooth muscle actin (a-SM actin), which
when present in cells, is indicative of a contractile or myofibroblast phenotype (Gabbiani 1998;
Yannas 2001). In skin wounds, staining for a-SM actin has provided visual evidence for the
presence of myofibroblasts in the wound site as well as their organized arrangement, which leads
to contraction and the formation of scar (Troxel 1994). Similarly, in nerves, cells expressing a-
SM actin form thick layers around the regenerating nerve tissue, and their presence has
contributed to the development of the pressure cuff theory of contraction in nerve wounds
(Chamberlain, Yannas et al. 2000).
2.4 Wound Healing at the Transcriptional Level
Although previous studies have demonstrated the important role that proteins play in
affecting the body's response to injury, recent studies involving peripheral nerves have also
shown that the wound healing response can be traced back to the transcriptional level where
bodily injury causes a change in expression of certain genes (Bosse, Kury et al. 2001; Costigan,
Befort et al. 2004; M6chaly, Bourane et al. 2006).
At least several other studies have also examined the change in gene expression of the
proteins mentioned above during wound healing. Studies examining gene expression in
wounded peripheral nerves demonstrated an up-regulation of TGF-P I compared to uninjured
nerve beginning as early as 12 hours after injury and persisting until up to two weeks after injury
(Nilsson, Moller et al. 2005; Beye, Hart et al. 2006). Similar studies that examined gene
expression in adult skin wounds have shown an up-regulation of TGF-P 1, TGF-P2, and TGF-33
as compared to unwounded skin (Soo, Hu et al. 2000); however, while up-regulation of TGF-p 1
peaked immediately after injury, the up-regulation of TGF-P2 and TGF-P3 seemed to lag behind
a bit with peak expression occurring five to seven days after injury (Frank, Madlener et al. 1996).
Finally, another study by Soo et al., mentioned above, specifically compared the gene
expression of TGF-P1, TGF-P2, and TGF-P3 in early fetal rat skin wounds and late fetal rat skin
wounds. In this study, TGF-pl was found to have higher gene expression in late fetal wounds
than in early fetal wounds. Conversely, TGF-P3 was found to have lower gene expression in late
fetal wounds than in early fetal wounds (Soo, Beanes et al. 2003).
2.5 Hierarchy of the Wound Healing Response
Thus, through extensive study of the wound healing response at many different levels and
across several different tissue types, the entire picture of the wound healing process begins to
emerge. Whether in an early fetus, late fetus, or an adult, the body's response to injury begins
with a change in gene expression levels. As gene expression levels change, a change in protein
expression at the wound site is also observed. These proteins, mostly in the form of cytokines
and other growth factors, initiate specific pathways dealing with cell migration, proliferation, and
differentiation, and eventually, this leads to a macroscopic change on the tissue level. Figure 2.3
provides a visual representation of this process.
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Figure 2.3 A graphic summary of the production of protein from genetic material through the
processes of transcription and translation.
As mentioned above, the introduction of regeneration templates, exogenous proteins, and
other treatments have been shown to change the end result of the body's response to injury. For
instance, in skin, partial skin regeneration can be achieved through the use of a dermal
regeneration template seeded with keratinocytes in contrast to the natural formation of scar in
adults. Similarly, in peripheral nerves, a collagen nerve regeneration template can virtually
eliminate the thick layer of contractile cells that normally surrounds the nerve regenerate.
These tissue level changes occur as a result of a change at the genetic level, the protein
level, or the cellular level. As this study focuses on the differences between regeneration
through the use of a collagen nerve regeneration template and regeneration through the use of a
silicone nerve regeneration template, one main goal of the experiment is to determine to what
extent the difference in implant type affects the wound healing response at the transcription
level.
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Chapter 3: Materials and Methods
3.1 Implant Preparation
3.1.1 Silicone Device Preparation
Silicone devices were prepared from silicone tubing (ID: 3.1 mm, Helix Medical, LLC,
Carpinteria, CA). In a sterile environment and using equipment sterilized in an autoclave, 16
mm segments of tubing were cut using microscissors. Each segment was then flushed twice with
sterile Phosphate Buffered Saline (PBS) solution and then placed in individual glass specimen
jars. Each device was then dehydrothermally treated in a vacuum oven for 48 hours at 120 OC
after which they were immediately sealed and placed in a dessicator with-DrieRite Absorbent
(VWR Internatinal, Inc., San Diego, California) until use.
3.1.2 Collagen Device Preparation
The first steps in production of collagen devices were the preparation of a collagen-GAG
slurry. Glacial Acetic Acid (GAA, Mallinckrodt Chemical Co., Paris, KY) was diluted to 3.0 M
concentration and a final volume of 1 ml. The solution was then drawn into a 3 ml syringe with
22 gauge needle (Cat. No. 309574, Becton Dickinson & Co., Franklin Lakes, NJ). Meanwhile,
0.25 grams of Type I Collagen (Integra Life Sciences, San Diego, CA) was dissolved in 4 ml of
ddH 20 in a separate 10 ml syringe (Cat. No. 309604, Becton Dickinson & Co., Franklin Lakes,
NJ). Then, the acetic acid solution was added to the syringe containing the collagen-water
suspension and mixed thoroughly. Further mixing was accomplished by attaching the 10 ml
syringe with the collagen slurry to another 10 ml syringe using a female-female Luer-lock
assembly (Stainless steel luer lock tube fitting, female luer x female luer, Cat. No. 5194k12,
McMaster-Carr Supply Company, New Brunswick, NJ) and transferring the solution back and
forth 10-15 times until the collagen fibers began to hydrate and the solution appeared uniform.
The slurry was then allowed to rest for 3 hours at room temperature to allow the collagen fibers
to swell. The syringe containing the slurry was then centrifuged in order to degas the solution.
After having prepared the slurry solution, the entire mixture was injected into closed
Teflon and aluminum molds (-0.25 ml per tube to create an outer diameter of 3.0 mm). To form
the 1.5 mm inner diameter, steel core mandrels (0.032" Dia., Cat. No. GWXX-320-30, Small
Parts, Inc., Miami Lakes, FL) with Teflon coating (PTFE Tubing, Cat. No. 06417-31, Cole-
Parmer Instrument Company, Vernon Hills, IL) were inserted into the molds and Teflon tubing
(PTFE Special Tubing, O.D. 0.125", I.D. 0.065", Cat. No. 06407-42, Cole-Parmer Instrument
Company) was used at the ends of the mandrels to space them in the center of the molds. The
molds were then placed in a freeze-drier for 1 hour at -40 oC. The tubes were then removed from
the molds and placed back into the freeze-drier at -40 oC. The vacuum pump was then activated
so that pressure below 100 mTorr was reached. The temperature was then raised to 0 oC for at
least 17 hours. Finally, the temperature was raised to 20 oC and the vacuum was released.
Finished tubes were placed in open aluminum foil bags and placed in a 120 'C oven under
vacuum (approximately -29.8 mmHG) for 48 hours. After this DHT treatment, the foil packets
were immediately closed and placed in a dessicator. This treatment allowed cross-linking in the
matrix tube and also sterilized the devices.
3.2 Rat Surgeries and Sacrifices & Sample Storage
3.2.1 Breakdown of Experimental Groups
87 animals were used in the experiment and were grouped in the following manner. For
animals implanted with silicone devices, 10 were sacrificed 1 day after injury, 10 were sacrificed
3 days after injury, 10 were sacrificed 7 days after injury, 10 were sacrificed 14 days after injury,
and 5 were sacrificed 21 days after injury. In total, 45 animals were implanted with silicone
devices. For animals implanted with collagen devices, 7 were sacrificed 1 day after injury, 10
were sacrificed 3 days after injury, 10 were sacrificed 7 days after injury, 10 were sacrificed 14
days after injury, and 5 were sacrificed 21 days after injury for a total of 42 animals that were
implanted with collagen devices.
3.2.2 Surgical Procedure of Nerve Wounding and Device Implantation
Adult, female Lewis rats with mass in the range of 150 - 200 grams were used in this
experiment (Charles River Laboratories, Willmington, MA). Prior to operation, rats were
anesthetized with sodium pentobarbital (50 mg of solution per kg of animal) and the leg
receiving the prosthesis was partially shaved (so that the hair was short) from the base of the tail
up to the middle of the back with the leg receiving the prosthesis shaved completely.(to remove
all hair). During operation, for each rat, one sciatic nerve was transected midway between the
proximal nerve trunk and the distal bifurcation using a scalpel. Marks were made 3 mm from
each end of the nerve stumps to indicate where the prosthesis would attach to the nerve ends.
The device being used was then trimmed to the proper length if necessary and 3 mm of each
nerve stump was inserted into either end of the tube. The nerve ends were secured in place by
using two 10-0 sutures which traveled through the epineurium and then through the tube and tied
off with 4 single knots. Sterile PBS was injected in the proximal end of the prosthesis to fill the
device.
Immediately following surgery, rats were placed in individual recovery beds with oxygen
masks. Analgesic was started immediately following surgery by injecting 0.1 ml of 0.15 mg/ml
Buprenorphine (approximately 0.1 mg/kg, Cat No. 40182C, Lyphomed, Deerfield, IL)
subcutaneously and continued for a minimum of 48 hours and then as often as needed. Cefazolin
was injected subcutaneously at 50 mg/day for three days. Once the anesthesia had worn off, rats
were placed in individual cages for the first week after surgery and then rats were combined two
to a cage after the first week.
3.2.3 Sacrifice Procedure and Sample Storage Protocols
Animals were sacrificed by being placed in a carbon dioxide chamber for 3 to 5 minutes.
The original wound was opened and the entire implant including at least 5 mm of proximal and
distal nerve tissue was removed. The explants were placed in rectangular R-40 Peel-A-Way@
Embedding Molds (PolySciences, Inc., Warrington, PA) that were filled with OCT embedding
medium. Additional OCT was added to cover the explants within the mold. The mold was then
lowered into liquid nitrogen but not immersed until the OCT was frozen. They were then
transferred to storage in a -80 'C freezer until ready for further processing.
3.3 Sample Cutting
After the nerves had been removed from the rat and frozen in OCT, they were ready to be
cut in preparation for RNA extraction. The procedure began by extracting the entire nerve
sample from the frozen OCT in a temperature controlled chamber. Ideally, the nerve samples
would have all been cut into five 3mm nerve segments labeled as segments #1-#5. Nerve
segment #1 would contain the proximal nerve stump, segment #2 would contain the material in
the nerve tube adjacent to the proximal stump, segment #3 would contain the material in the very
middle of the tube, segment #4 would contain the material in the tube adjacent to the distal
stump, and segment #5 would contain the distal nerve stump (Figure 3.1).
3mm
Proximal Nerve Stump Distal Nerve Stump
Segment #: 1 2 3 4 5
Figure 3.1 Diagram depicting the ideal outcome of cutting nerve samples into five 3mm
segments with segment #1 containing the proximal nerve stump and segment #5 containing the
distal nerve stump.
In practice, this was rarely possible since the tubes were not always exactly 10mm in length,
also, due to human error during surgery as well as movement of the rats during healing, the nerve
stumps did not always extend exactly 3mm into the tubes. Nevertheless, because the real-time
PCR protocol did not require that samples have constant mass or volume, it was decided that
regardless of length, nerve segment #1 should always include the entire proximal nerve stump
and nerve segment #5 should always contain the entire distal nerve stump. Whenever possible,
the segments lengths were kept to 3mm, but when segments #1 or #5 needed to be longer than
3mm, the remaining segments (#2 - #4) ended up being slightly shorter than the ideal 3mm.
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The cutting of explanted nerves took place in a temperature controlled cryostat chamber
set to -250 C with the use of razor blades and disposable scalpels. Figure 3.2 provides an
example of a silicone tube nerve sample before and after being cut.
Figure 3.2 (a) Uncut silicone sample after extraction from OCT (b) Four segments of a cut
silicone sample.
After removing as much OCT from the nerve regenerate as possible, the nerve samples were cut
into segments according to the aforementioned guidelines with the use of a metric ruler to
measure the length of the segments. To prevent contamination between segments, the cutting
tool was rinsed in methanol between every cut and was dried off with gauze. After cutting, the
silicone tube was removed from the nerve segments but collagen tubes were left along with the
nerve regenerate. Cut segments were then placed in individual 1.5 mL Eppendorf tubes. The
tubes were labeled with the serial number of the rat that the nerve sample came from, the number
of days after injury that the sample was taken, the type of implant that was used, and the segment
number. For example, 723D 14C2 would refer to segment #2 of a nerve sample taken from rat
#723 that had been sacrificed fourteen days after injury and which had been treated with a
collagen implant. The samples were then stored at -800 C until RNA extraction was performed.
3.4 RNA Extraction & Reverse Transcription
RNA extraction was performed using the Arcturus PicoPure RNA Isolation Kit
(Molecular Devices, Sunnyvale, CA). The procedure began with the addition of 30tL of
extraction buffer in order to break down the cellular material into molecular components. Each
sample was incubated in this extraction buffer for 30 minutes at 420C. The solution was then
centrifuged to separate the soluble components from undigested tissue and the supernatant was
transferred to a new 1.5 mL Eppendorf tube. Next, 30 ýiL of 70% ethanol was added to each
solution in order to precipitate out the genetic material.
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Meanwhile, a filter column was prepared by incubating in conditioning buffer for 5
minutes at room temperature. The columns were then centrifuged to elute out the conditioning
buffer and the solution prepared from the nerve tissue was added to individually labeled filter
columns. The column was then spun at a relatively slow speed to allow the genetic material to
bind to the filter and then spun at a high speed to elute out the remaining soluble waste. Because
ethanol precipitates out both DNA and RNA, a DNAse mixture (Qiagen RNAse free DNAse Set,
Qiagen, Valencia, CA) was added to digest any DNA, which was washed out with a series of
wash buffers from the RNA isolation kit. Lastly, the columns were transferred to fresh 0.5mL
Eppendorf tubes and the purified RNA was eluted out with the use of elution buffer.
Because purified RNA is not very stable and is easily subject to degradation, after RNA
extraction, samples always immediately underwent reverse transcription to convert the RNA to
cDNA, which is a much more stable single-stranded form of genetic material that uses thymine
instead of uracil. The reverse transcription protocols were carried out using the Invitrogen
Superscript III First-Strand Synthesis System for real-time PCR (Invitrogen, Carlsbad, CA). The
first step in the process was to add a solution containing a mixture of random hexamer primers
and individual nucleotides to each RNA sample. The samples were then incubated at 650C for
five minutes in a PXE 0.2 Thermal Cycler in order to allow the primers to bind to the RNA.
Next, a cDNA synthesis solution containing various buffers, the reverse transcriptase enzyme,
and cofactors was added to each RNA sample. The samples were then placed back into the
thermal cycler where they are incubated at 25'C for ten minutes, then 500 C for 50 minutes, and
finally 85oC for 5 minutes. During this process, the reverse transcriptase made a cDNA copy of
the mRNA in the solution starting from the hexamer primer. This cDNA was then separated
from the mRNA and the remaining mRNA was digested using RNAse H. Because of the
stability of cDNA, the samples were then able to be stored at -20 0 C for up to months and even
years without significant decrease in signal.
3.5 Checking cDNA & Performing Real Time Polymerase Chain Reaction
(PCR)
3.5.1 Theory and Mechanics of Real-time PCR
Real Time PCR was carried out in Applied Biosystem's 7300 Real-Time PCR System
(Applied Biosystems, Foster City, CA). The theory behind real time Polymerase Chain Reaction
(PCR) is that by cyclically copying a particular gene in various samples and determining how
many cycles it takes for each sample to reach a threshold value, one can compare the relative
amounts of genetic material in the original samples.
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Figure 3.3 A flowchart demonstrating the different steps involved in PCR. In a perfect reaction,
after each cycle, the number of copies of the gene of interest doubles. Since the signal is
exponentially amplified, PCR provides a relatively quick way of determining differences in gene
expression <http://www.copernicusproject.ucr.edu/ssi/HSBiologyResources.htm>.
Figure 3.3 provides a visual summary of the entire process. The general procedure for carrying
out real-time PCR consists of adding cDNA to a solution containing a master mixture of buffer,
enzymes, and cofactors as well as fluorescently tagged primer for the gene of interest. This
solution is then placed in the machine which cycles through several temperature settings in order
to create copies of the gene of interest. Each cycle consists of a denaturation step in which
double stranded material is separated. Then, an annealing step allows the primers to bind to the
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gene of interest. Lastly, the elongation step consists of the creation of a new strand of genetic
material by transcription enzymes in solution
In theory, every time the machine completes a replication cycle, there should be twice as
many copies of the gene of interest as before the last cycle. Every time the gene of interest is
copied, a primer is used and the fluorescent tag that was initially attached to the primer gets
cleaved. After each cycle of replication, the machine reads the amount of fluorescence of the
solution. This reading is proportional to the number of copies that have been made. Thus, if a
sample has a high fluorescence reading after a small number of cycles, it means that the gene of
interest was highly expressed in the original sample. Conversely, if the sample takes many
cycles to reach a high fluorescence value, it means that the gene of interest was only expressed at
low levels in the original sample.
3.5.2 Checking cDNA
Before running real-time PCR to examine the genes of interest in this study, after reverse
transcription was complete, every sample was checked in order to make sure that an adequate
amount of cDNA was present in the sample. This was done to prevent waste of materials on
samples that did not contain sufficient levels of total cDNA to produce a significant signal. A
small amount of cDNA was added to a mixture of Taqman Universal PCR Master Mix (2x),
Taqman Gene Expression Assay (20x) for Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), and water (Applied Biosystems, Foster City, CA). GAPDH is an enzyme involved in
metabolic pathways which exists at relatively constant levels in all cells. Its use as a
housekeeping gene is discussed in detail in the following section.
These solutions were then added to 96-well plates in duplicate so that each solution was
placed in two separate wells. By running PCR on samples in duplicate, it provided a method for
verifying that outlying or unexpected results were indeed accurate and were not due to human
error in plate setup or random glitches by the machine. Plates were then vortexed, centrifuged
and placed into the PCR machine. The program that the machine followed was as follows: 500 C
for two minutes, 950 C for ten minutes, then 40 cycles of 95oC for 15 seconds followed by 60 0 C
for one minute. A sample was deemed containing sufficient amount of total cDNA if
fluorescence began to spike before 35 cycles. Any samples that showed fluorescence spikes
after 35 samples contained a very small amount of cDNA; moreover, samples that required that
many cycles to achieve significant fluorescence had a higher likelihood of exhibiting a false
positive signal due to erroneous non-specific binding of primers to cDNA.
3.5.3 Real Time PCR for Genes of Interest
Real-time PCR for the aforementioned genes of interest proceeded much like the process
used to check the cDNA, but there were several differences. During sample preparation, a
different master solution had to be made for each gene of interest using a different primer. For
each gene (fibronectin, TGF-31, TGF-P2, TGF-P3, and a-SM actin), Taqman Gene Expression
Assays (Applied Biosystems, Foster City, CA ) for the specific genes of interest were used.
Additionally, instead of performing the experiments in duplicate, each test was run in triplicate,
so that three independent data points could be gathered to ensure consistency of results.
In addition to each of the genes of interest, a sixth housekeeping gene was used as a
standard of the total amount of cDNA in each sample. For this experiment, we used GAPDH, a
gene that has been used in many other studies including those used in wound healing (Soo, Hu et
al. 2000; Soo, Beanes et al. 2003). By taking the ratio of signal found when studying a particular
gene of interest to the signal found using the housekeeping gene for a particular sample, we
normalized the signal of our gene of interest to the total amount of cDNA present in the sample.
This method of using a housekeeping gene accounted for any variation in cell count or cell
activity between samples.
3.6 Methods for Analyzing Real-Time PCR Data
3.6.1 2-Aact Method for Quantitative Real-Time PCR Data Analysis
The real-time PCR machine output consisted of a graph that tracked the fluorescence
level in the samples to be analyzed over each cycle performed. Figure 3.4 shows a typical data
output from the Applied Biosystems 7300 Real-time PCR system.
Figure 3.4 A typical output reading from Applied Biosystem's 7300 Real-time PCR system.
In an ideal reaction, after each cycle, the amount of cDNA doubles, which means that there the
growth of signal with respect to cycle number is exponential. Based on this fact, the 2AAct
method has been developed to allow comparison of genetic expression in different samples
(Livak and Schmittgen 2001).
The ultimate goal of this study was to compare the gene expression of particular target
genes in regenerating nerves that used silicone implants to regenerating nerves that used collagen
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implants. According to the 2 -_ACt method (Livak and Schmittgen 2001), in order to compare the
real-time PCR data from these samples, several conditions need to be met. First, each sample
needs to be normalized against an internal control. The housekeeping gene (GAPDH) served
this purpose. By dividing the number of target molecules present at the threshold level by the
number of internal reference molecules present at threshold, we got an internally normalized
value for the amount of target. Next, the data had to be normalized against a calibrator, which
was specifically selected depending on the goal and purposes of the study. In this study, any of
the studied samples could have served as the calibrator, so the internally normalized fibronectin
data from the nerve implant of rat #745, which received a silicone implant for one day before
sacrifice, was used as the calibrator. This means that each internally normalized data point was
then divided by the calibrator. Because the data was in the form of cycle numbers, and this
equates to an exponential growth with base 2 (the total number of replicates doubles after each
cycle), the resulting equation was:
# of target molecules = 2
-AACt
where AACt = [(cycle number of target gene to reach threshold) - (cycle number of
housekeeping gene to reach threshold)] - [internally normalized calibrator].
The result was a set of data that represents the relative amount of cDNA in the original sample.
Since the cDNA was derived from the mRNA in the original nerve segments, this allowed us to
compare relative amounts of our target gene expression in the original nerve segments.
3.6.2 Statistical Analysis Methods
Once this set of data was obtained, the use of statistical methods was employed to
determine whether there is a significant difference between compared samples. The purpose of
this study was to compare the level of gene expression in samples at different time points that
used different implant material. Thus, each data point in the set had only one other primary point
of comparison. For instance, data from rats implanted with silicone for fourteen days were
primarily compared with data from rats implanted with collagen for fourteen days.
Consequently, the statistical analysis method of choice was the two-tailed student's t-test for two
samples of equal variance (homoscedastic). This was best because it specifically compared two
sample sets to determine whether they were significantly different. This method differs from
ANOVA which is a method to determine whether there is significant variation in many different
sample sets.
For each gene of interest (fibronectin, TGF-Pl, TGF-P2, TGF-P3, and a-SM actin), the
first step in the statistical analysis was to average the data in each sample set to obtain a sample
mean for sample sets that were in the same implant group (silicone vs. collagen), temporal group
(day 1, 3, 7, 14, or 21), and had the same segment number (#1 - #5). Sample means of a
particular implant group, temporal group and segment number were then compared to the
corresponding sample mean in the other implant group using a two-tailed homoscedastic
student's t-test to determine whether they were significantly different (P < .05).
Additionally, the aforementioned sample means that were in the same group were
averaged to find an average value for relative gene expression over entire nerve samples as
opposed to for individual nerve segments. These averaged sample means were then compared to
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the temporally corresponding averaged sample means in the other implant group using a two-
tailed homoscedastic student's t-test with P < .05 denoting statistical significance. Besides
averaging sample means to obtain averaged sample means for entire nerve segments, we were
also interested in comparing the averaged sample means of segments that contained nerve
stumps (#1 & #5) that were in different implant groups as well as averaged sample means of
segments that constituted the gap between nerve stumps (#2-#4). These averaged stump sample
means and averaged gap sample means were also compared to their temporally corresponding
averaged stump and gap sample means in the other implant group using a two-tailed
homoscedastic student's t-test with P < .05 denoting statistical significance. Finally, this entire
statistical analysis was then repeated for each gene of interest.
Chapter 4: Data Analysis
4.1 Fibronectin
Only a handful of nerve segments demonstrated statistically significant differences
between silicone and collagen implants (Section 4.6). Temporally, these differences were found
mainly at the day 3 and day 7 time points. Spatially, it was the segments containing the nerve
stumps that demonstrated significant differences in fibronectin expression between the different
implant groups. Figure 4.1 shows the relative quantity of fibronectin expression in the studies
nerves by segment. Bars of the same color (or bars that are adjacent to each other) represent
sample means of nerve segments that were obtained from the same temporal group and implant
material group. For each color (or cluster of bars), the five bars represent the sample means of
the five nerve segments from #1 to #5 starting from left to right. The data for the silicone
implant group is on the left and the data for the collagen implant group is on the right. The error
bars indicate one standard deviation above or below the mean and bars with asterisks above them
indicate that those sample means were significantly different (p<.05) than the sample means for
the corresponding data sets in the other implant group.
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Figure 4.1 Chart of relative levels of fibronectin mRNA expression in different nerve segments.
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The averaged sample means (Figure 4.2) provide a less detailed but simpler
representation of the differences between the collagen and silicone implant groups as well as the
kinetics of fibronectin mRNA expression in each type of implant. Each bar represents the
average of the segment sample means for a given temporal and implant material group. Once
again, the error bars represents one standard deviation above and below the mean and an asterisk
above the bar indicates that the averaged sample mean was significantly different (p<.05) from
the averaged sample mean for the same temporal group but different implant group. Day 3 and
day 7 showed significant differences in fibronectin mRNA expression between silicone and
collagen implants. The use of collagen implants caused a lower level of fibronectin mRNA
expression than the use of silicone implants. Additionally, the expression of fibronectin mRNA
remained fairly constant when silicone implants were used in the wound site while the use of
collagen implants was accompanied by a significant decrease in fibronectin mRNA expression
during days 3 and 7.
Figure 4.2 Chart of relative levels of fibronectin mRNA expression that were
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The final chart is a visual representation of the data found when segments that contained
nerve stumps are examined separately from the segments that comprised the gap between nerve
stumps (Figure 4.3).
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Figure 4.3 Chart of relative levels of fibronectin mRNA expression where stump data (segments
#1 and #5) were averaged and separated from the averaged gap data (segments #2-#4).
In the case of fibronectin, analysis of the stump data separately from the gap data did not provide
any new statistically significant differences between the collagen and silicone implant groups.
The only result of note was that in the silicone implant group, aside from the first day, the level
of fibronectin mRNA expression in the nerve stumps and in the gap tended to be about the same
while in the collagen implant group, the fibronectin mRNA expression in the gap was
consistently higher than the expression in the nerve stumps.
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4.2 Transforming Growth Factor-beta 1
The charts for the remaining genes of interest all follow the same format as the charts that
track fibronectin mRNA expression (refer to section 4.1 for chart explanation). Figure 4.4 shows
the sample means of individual nerve segments sorted by temporal group and by implant group
for TGF-P 1.
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Figure 4.4 Chart of relative levels of TGF-31 mRNA expression in different nerve segments.
In this case, virtually no segment sample means showed a statistically significant difference
between the corresponding segment sample mean in the other implant group. Out of 25
individual segment pairs, only 3 demonstrated a statistically significant result.
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chart of averaged sample means (Figure 4.5) shows a similar result. The only
significant difference between the silicone and collagen implant groups was at day 7.
Figure 4.5 Chart of relative levels of TGF-11 mRNA
entire nerve.
expression that were averaged across the
In terms of expression kinetics, the amount of TGF-3 1 mRNA expression increased slightly and
steadily over time in the silicone group; however, in the collagen group, no such trend was
found. The levels of TGF-31 mRNA expression in the collagen group remained relatively steady
except for a small dip at day 7.
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No new statistically significant results were found in the separate analysis of the stump
and gap data; however, in terms of expression kinetics, the trend of increasing TGF-3 1 mRNA
expression in silicone was supported by the stump data but not by the gap data. Thus, the
observed trend in Figure 4.6 seems to be caused mainly by changes in expression in the nerve
stumps rather than in the gap. Similarly, in the collagen group, a more pronounced increase in
TGF-31 mRNA expression is noticed at later time points when examining the segments that
contained nerve stumps.
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Figure 4.6 Chart of relative levels of TGF-31 mRNA expression where stump data (segments #1
and #5) were averaged and separated from the averaged gap data (segments #2-#4).
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4.3 Transforming Growth Factor-beta 2
TGF-P2 also showed very limited differences between the collagen and silicone implant
groups. In general, the mRNA expression levels remained about the same for both implant
groups. The only individual segments that showed statistically significant differences were on
day 21 (Figure 4.7).
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Figure 4.7 Chart of relative levels of TGF-P2 mRNA expression in different nerve segments.
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This trend continued until day 21 when the expression of TGF-32 significantly increased but
much more so in the silicone group than in the collagen group. This can best be seen in Figure
4.8, which shows the averaged sample means.
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The chart of separate stump and gap data also supports the trend that both the silicone and
collagen implants expressed steadily increasing but similar levels of TGF-P2 mRNA until day 21
when the silicone group spiked a little higher than the collagen group (Figure 4.9).
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Figure 4.9 Chart of relative levels of TGF-P2 mRNA expression where stump data (segments #1
and #5) were averaged and separated from the averaged gap data (segments #2-#4).
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4.4 Transforming Growth Factor-beta 3
The general trend of expression of TGF-f3 in both the silicone group and collagen group
was that expression levels rise with time after injury. The difference, however, was that mRNA
expression levels reached peak levels by day 14 after injury in the collagen group while in the
silicone group, the expression levels did not reach peak levels until 21 days after injury. 6 out of
25 pairs of segment sample means showed a statistically significant difference (Figure 4.10).
Two of these results came at day 7 at segments #2 and #3 and demonstrated a higher level of
TGF-P3 mRNA expression in the silicone group than in the collagen group. By day 14,
segments #2-#5 in the collagen group showed a significantly higher level of TGF-03 nMRNA
expression than the corresponding segments in the silicone group.
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Figure 4.10
This result was further supported by the analysis of averaged sample means (Figure 4.11). While
both silicone and collagen groups reached the same relative values by day 21, the collagen group
demonstrated a significant spike in TGF-33 mRNA expression while the silicone group remained
at a relatively low level of expression.
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Figure 4.11 Chart of relative levels of TGF-P3 mRNA expression that were averaged across the
entire nerve.
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Separate analysis of the nerve stumps and gap data (Figure 4.12) revealed that the nerve stumps
seemed to undergo a sharp rise in TGF-P3 mRNA expression before the gap segments do. After
two weeks, the expression levels in the collagen group's nerve stump segments spiked to high
levels while the segments comprising the gap only increased about half as much. By day 21,
however, the gap segments' mRNA expression levels had caught up to those segments that
contained the nerve stumps, which remained constant between the 2 nd and 3 rd weeks. The
silicone group seemed to lag in both areas: the TGF-p3 expression levels at day 21 closely
resembled the TGF-P3 expression levels of the collagen group at day 14 for both the nerve stump
segments as well as the gap segments.
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Figure 4.12 Chart of relative levels of TGF-P3 mRNA expression where stump data (segments
#1 and #5) were averaged and separated from the averaged gap data (segments #2-#4).
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4.5 alpha-Smooth Muscle Actin
a-SM actin was the last gene of interest to be studied. Especially at later time points,
several segment sample means were significantly different between the silicone and collagen
implant groups (Figure 4.13). Spatially, these differences were mostly observed closer to
segments #1 and #5 until day 21 at which point all of the segments demonstrated different levels
of a-SM actin mRNA expression.
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Taking a look at the averaged sample means across the entire nerve (Figure 4.14), a simpler
picture of the a-SM actin mRNA expression levels came to light. For the first two weeks, both
silicone and collagen groups saw a slow and steady rise in a-SM actin mRNA expression levels
with the collagen group slightly lagging behind the silicone group; however, at day 21, the
silicone group underwent a significant increase in mRNA expression levels which was not
observed in the collagen group.
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Figure 4.14 Chart of relative levels of a-SM actin mRNA expression that were averaged across
the entire nerve.
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The separated stump segments and gap segments data (Figure 4.15) revealed that differences in
mRNA expression level existed mainly at the nerve stumps. At days 7, 14, and 21, the segments
containing the nerve stumps showed a much higher level of a-SM actin mRNA expression in the
silicone group than in the collagen group. The segments comprising the gap did not demonstrate
significant difference in expression until day 21.
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Figure 4.15 Chart of relative levels of a-SM actin mRNA expression where stump data
(segments #1 and #5) were averaged and separated from the averaged gap data (segments #2-#4).
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4.6 Tabulation of Statistical Significance
The following table is a compilation of the differences between mRNA expression levels
of wounds treated with a collagen versus those treated with a silicone device that are statistically
significant (p<.05). Empty cells denote that there was not a statistically significant difference for
that spatial or temporal data point.
Fibronectin Day 1 Day 3 Day 7 Day 14 Day 21
Segment #1 Silicone Silicone Silicone
Higher Higher Higher
Segment #2 Silicone
Higher
Segment #3
Segment #4
Segment #5 Silicone Silicone
Higher Higher
TGF-pl Day 1 Day 3 Day 7 Day 14 Day 21
Segment #1 Collagen
Higher
Segment #2
Segment #3 Silicone
Higher
Segment #4
Segment #5 Silicone
Higher
TGF-P2 Day 1 Day 3 Day 7 Day 14 Day 21
Segment #1
Segment #2 Silicone
Higher
Segment #3
Segment #4 Silicone
Higher
Segment #5
TGF-J3 Day 1 Day 3 Day 7 Day 14 Day 21
Segment #1
Segment #2 Silicone Collagen
Higher Higher
Segment #3 Silicone Collagen
Higher Higher
Segment #4 Collagen
Higher
Segment #5 Collagen
Higher
a-SM Actin Day 1 Day 3 Day 7 Day 14 Day 21
Segment #1 Silicone Silicone
Higher Higher
Segment #2 Silicone Silicone
Higher Higher
Segment #3 Silicone
Higher
Segment #4 Silicone
Higher
Segment #5 Silicone
Higher
Segment Averages Day 1 Day 3 Day 7 Day 14 Day 21
Fibronectin Silicone Silicone
Higher Higher
TGF-PI Silicone
Higher
TGF-P2 Silicone
Higher
TGF-P3 Collagen
Higher
a-SM actin Silicone Silicone
Higher Higher
Chapter 5: Discussion and Conclusions
5.1 Discussion of Results
The experiment produced a vast amount of data, which after a thorough analysis resulted
in only a few statistically significant differences between the two devices.
Fibronectin has been shown to be an important component in the provisional matrix that
appears very early in healing wounds. As such, it was expected that fibronectin mRNA
expression would be steady and significant. The results from the silicone group demonstrated
this kind of expression profile; however, in the collagen group, despite showing an initially high
expression of fibronectin mRNA, by day 3, the expression levels had dropped significantly and
did not increase again until the 2 nd to 3 rd week (Figure 4.2). This drop in fibronectin mRNA
expression is difficult to explain. Despite the presence of a collagen matrix at the wound site,
fibronectin synthesis would still be required to allow cellular adhesion sites that would allow
cellular migration into the injured nerve. Some possible explanations include that, as was
mentioned before from Yannas 1975, Yannas 1989, and Yannas 1990 data, the collagen scaffold
has been shown to prevent aggregation of platelets, which may result in a decreased level of
fibronectin production. Also, other studies have shown that cellular expression of fibronectin
mRNA as well as the actual secretion of fibronectin is heavily dependent on combinations of
particular proinflammatory cytokines (Kitamura, Nishinarita et al. 2000), which may have been
down-regulated in some unobserved fashion. Comparing fibronectin expression by the collagen
group to that of early fetal wound healing, it is unclear whether the lower expression of
fibronectin mRNA is due to the recently studied (Li-Korotky, Hebda et al. 2007) down-
regulation of spliced fibronectin variants found in early fetal wound healing since different
variants of fibronectin mRNA were not studied in this experiment.
In this study, TGF-P31 maintained fairly steady mRNA expression throughout the entire
period of study (1 day after injury until 3 weeks after injury) for both implant groups. TGF-P1
has been highly implicated in contraction and scar formation as a cytokine responsible for the
differentiation of fibroblasts into myofibroblasts. Moreover, TGF-P31 mRNA expression has
been shown to be much lower in early fetal wounds than in late fetal wounds (Soo, Beanes et al.
2003). This study, however, failed to find significant differences in TGF-11 mRNA expression
between the silicone implant group and collagen implant group. Thus, with respect to TGF-P31
mRNA expression, the collagen nerve regeneration template does not seem to parallel the fetal
wound healing response. The expression kinetics observed in this study are fairly similar to the
expression kinetics found in other studies of TGF-P1 mRNA expression in untreated skin
wounds, which showed a sharp increase in TGF-P31 mRNA expression as early as at 1 day after
injury and peaked at around 7 days after injury. These results demonstrate a similar expression
profile for the first week after injury, however, the levels of mRNA expression do not decline
even after three weeks as observed in skin studies.
TGF-p2 also demonstrated no significant patterns of expression in this study. The only
significant difference in TGF-02 mRNA expression between the silicone and collagen implant
groups was found at 21 days after injury, but this was due to a sharp spike in expression in the
silicone group; however, no real trend was found. The delayed up-regulation of TGF-32 mRNA
is consistent with observation from skin studies that found a delay in TGF-02 mRNA up-
regulation as compared to TGF-P31 in untreated wounds (Frank, Madlener et al. 1996; Soo, Hu et
al. 2000; Soo, Beanes et al. 2003). In these studies, TGF-12 mRNA expression did not begin to
rise until up to 1 or 2 weeks after injury. Based on the observation that nerve wound expression
kinetics seem to be delayed compared to the expression kinetics found in skin wound studies, the
spike at 21 days after injury in TGF-P2 mRNA expression may indicate the beginning of a late-
appearing trend in the nerve wounds. Moreover, in a short-term comparison of TGF-p2 mRNA
expression in early fetal wounds to late fetal wounds (Soo, Beanes et al. 2003), no real difference
in TGF-P2 mRNA expression was found up to three days post-injury in skin. Ultimately,
however, because of the lack of long term data regarding TGF-P2 expression in early fetal
wounds, it is unclear whether the expression profile in the collagen group parallels early fetal
wound healing expression.
The last cytokine of interest that was studied was TGF-33, which demonstrated a small
yet significant difference in mRNA expression between the silicone and collagen groups. The
results of the experiment indicated that a significant up-regulation of TGF-33 was present in the
collagen implant group 14 days after injury. The silicone group experienced a similar significant
increase in TGF-p3 mRNA expression but not until 21 days after injury. Prior research has
shown that in typical late fetal and adult wound healing in skin, significant TGF-P3 mRNA up-
regulation is not observed until around one week post-injury (Frank, Madlener et al. 1996; Soo,
Hu et al. 2000), which is consistent with the results in this study assuming that the expression
kinetics profile in nerve wounds is temporally elongated as compared to that of skin. Other skin
studies have also recognized that in both wounded and non-wounded tissue, the early fetus
maintains a higher level of TGF-33 mRNA expression than the late fetus (Soo, Hu et al. 2000;
Soo, Beanes et al. 2003). While this study shows that the TGF-33 mRNA expression in the
collagen group reached significant up-regulated levels quicker than the silicone group, it is only
poor support for the claim that the collagen nerve regeneration template causes the adult body's
mRNA expression during wound healing to mirror that of the early fetus.
Finally, a-SM actin, while not an inflammatory cytokine, has been shown to play an
important role in contraction, which comprises much of the wound healing response in late
fetuses and adults. In this study, despite the absence of very significant differences in expression
of the TGF-3 cytokine family between silicone and collagen implant groups, there were
significantly different levels of a-SM actin mRNA expression found at later time points in the
experiment. Because a-SM actin is an indication of the presence of actively contracting
myofibroblasts, this lower level of a-SM actin mRNA expression in collagen suggests the
absence of the thick capsule of contractile cells that is generally found in nerve wounds treated
with silicone tubes. Although the differences in a-SM actin mRNA expression up to two weeks
after injury were fairly marginal, the sharp increase in expression in the silicone group at 21 days
after injury may indicate the beginning of a trend of increasing a-SM actin mRNA expression in
the silicone group that is not observed in the collagen group. Moreover, in previous observations
of the contractile capsule in nerve wounds, the earliest observed time point was six weeks
(Chamberlain, Yannas et al. 2000), which was much later than the temporal scope of this study.
Thus, the period of two to six week post injury in nerves may provide much more conclusive
results with regards to a-SM actin mRNA expression in wounded nerves.
In general, the mRNA expression kinetics in nerve wounds seem to have a much more
temporally elongated profile than the kinetics profile observed in prior skin wound studies.
Moreover, the lack of significant nerve wound healing studies examining these particular
proteins during the same time period after injury make it difficult to confirm the results.
Nevertheless, they seem consistent with the macroscopic observations found in prior nerve
studies.
5.2 Conclusions of the Study & Tentative Rejection of the Hypothesis
The goal of this study was to determine whether the presence of a collagen nerve
regeneration template in a wounded nerve affects the mRNA expression of inflammatory
proteins as compared to their expression in wounded nerves treated with silicone tubes. Previous
studies have shown that using a collagen tube produces smaller contractile layer and a higher
quality regenerate than using a silicone tube (Chamberlain, Yannas et al. 2000). If the
discrepancy in regenerated nerve quality was due to differences at the transcriptional level, it was
expected that the mRNA expression of inflammatory proteins would be significantly lower in
rats treated with collagen tubes as opposed to those treated with silicone tubes.
In studying the mRNA expression of the TGF-3 cytokines, if indeed the hypothesis were
true, we expected to find significantly higher expression of TGF-3 1 and TGF-P2 mRNA in the
silicone group as compared to the collagen group, and a much higher expression of TGF-33
mRNA in the collagen group as compared to the silicone group. There was no significant trend
observed for TGF-P31 and only one time point demonstrated statistically significant levels of
expression in both TGF-P2 and TGF-f3 (See Figures 4.5, 4.8, and 4.11). While these slight
differences and observed trends may contribute to the differences in regeneration induced by
silicone tubes versus collagen tubes, we would expect to see significantly different levels of
mRNA expression at many different time points and across multiple cytokines before accepting
the hypothesis. Therefore, the conclusion of this study is that significant differences in mRNA
expression of inflammatory cytokines do not exist between nerve wounds treated with silicone
tubes as opposed to collagen tubes. While small differences in expression do exist, they do not
seem significant enough to affect the observed differences in regeneration between the two
implant types, which suggests that the underlying cause of the discrepancy in regeneration
quality is due to differences at the translation or protein interaction level.
In addition to observing mRNA expression of TGF-3 family of cytokines, the expression
of a-SM actin mRNA was also studied. Although TGF-P31 and TGF-02 did not show
significantly different levels of mRNA expression between implant types, a-SM actin mRNA
expression levels demonstrated very significant differences at later time points in the study. This
suggests that despite the lack of change in TGF-P31 and TGF-p2 expression in nerves treated with
collagen tubes, the amount of myofibroblast activity (as indicated by levels of a-SM actin
expression) was lower in the collagen group than the silicone group. Such a result further
supports the finding that the contractile myofibroblast layer is much smaller in collagen treated
wounds than those treated with silicone. Moreover, this difference is most likely caused at the
protein expression or protein interaction level since the transcription levels of TGF-3 cytokines
are not significantly different between implant groups. Nevertheless, these conclusions could be
more solidly supported by future transcriptional studies that examine the mRNA expression of
inflammatory proteins and especially contractile elements during the three to six week time
period.
5.3 Discussion of Error & Variability
In this study, there were significant sources of variation in protocol execution as well as
animal to animal variability; however, as much as possible, larger sample sizes were used to
minimize the effect of such variability and procedural error on the results.
The primary source of variation between different nerve samples was due to animal to
animal variability. In this study, despite the use of up to ten rats in a particular sample, the
standard deviation of the data was often greater than 50% of the mean value. Because of this
variability, in order to find statistical significance, large sample sizes were used.
Other sources of error could be caused by variation in procedural execution. For
example, in cutting the nerve tissue, a mechanical metric ruler and a razor blade were used, and
cuts were made by hand. Additionally, because the place at which the nerve stump ended and
the gap began was different across different nerve samples, it was difficult to consistently cut the
segments accurately. But, while this may have contributed to error in the study of the individual
nerve segments, it would not have contributed to erroneous results in the data of mRNA
expression averaged over the entire nerve. Studying the average mRNA expression over the
entire nerve was one way to observe differences while minimizing sources of error due to
procedure.
A third source of error that would have a similar effect as the cutting error, is the fact that
in silicone tubes with a gap length of 10mm, reconnection only occurs about 50% of the time.
Because we expect a difference in mRNA expression between wounded nerves that have
reconnected and wounded nerves that are forming a neuroma, this would also contribute to error
in the data since we had no way of observing or accounting for which nerves formed a neuroma
and which nerves were able to reconnect. In order to work around this source of error, the
analysis of only segments containing nerve stump and only segments comprising the nerve gap
were studied separately to see if differences or separate trends existed; however, because for the
most part, no significantly different results or trends were found, this does not seem to be a
significant source of error.
A final source of possible error is due to human or machine error while setting up and
running real-time PCR. In such a repetitive environment, it may be easy to miss adding the
proper amount of reagents to each well in the plate; however, because each sample was run in
triplicate, it was very easy to find and eliminate data caused by such errors. While this study had
many opportunities for error and variability, by using particular groupings during the analysis of
data, using large sample sizes, and using rigorous protocols for mRNA extraction, reverse
transcription, and real-time PCR, the effect of these errors and variability was mitigated.
Nevertheless, repeat studies to confirm or refute these results would highly strengthen the
findings.
5.4 Future Work & Direction of Study
Based on the results achieved in this study, it seems clear that the differences in
regenerate quality between nerves treated with silicone tubes as opposed to collagen tubes are
probably not due to discrepancies at the transcriptional level. Return to the following figure,
which illustrates the different levels of expression at which differences in wound healing
response may manifest themselves. The next logical step is to look at protein expression.
Figure 5.1 A graphic summary of the production of protein from
processes of transcription and translation.
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Most likely the differences occur at the level of protein translation or at the level of protein
interactions. There are at least several reasons why differences observed at the cellular level may
not be due to differences at the transcriptional level. For example, recently studied microRNAs
are non-coding sequences of RNA that serve to down-regulate gene expression by binding to
specific mRNA molecules to prevent translation (Lau, Lim et al. 2001). Other such regulatory
mechanisms whether acting on mRNA or at other points along the translational pathway can
prevent translation of mRNA to protein (Ma, Horvath et al. 2008; Narasimhan, Joyce et al.
2008). Additionally, there are many other factors that can affect cell activity, proliferation, and
differentiation including the mechanical and chemical environment as well as the presence or
interaction of other proteins in particular signaling pathways (Farrell, O'Brien et al. 2006; Jiang,
Xia et al. 2008). Thus, by comparing the protein expression of these inflammatory cytokines in
nerve wounds treated with silicone and collagen tubes, the list of possible sources of discrepancy
in regeneration quality can continue to be narrowed down.
udGenetic Material
Cytosoi
- Transcription
Translation
Nascent
protein
! 1 _
References
. "High School Biology Resources." from
http://www.copemicusproject.ucr.edu/ssi/HSBiologyResources.htm.
Azzam, N. A., A. A. Zalewski, et al. (1991). "Nerve cables formed in silicone chambers
reconstitute a perineurial but not a vascular endoneurial permeability barrier." The
Journal of Comparative Neurology 314(4): 807-819.
Bertoldo, F., L. D'Agruma, et al. (2000). "Transforming growth factor-betal gene polymorphism,
bone turnover, and bone mass in Italian postmenopausal women." J Bone Miner Res
15(4): 634-639.
Beye, J. A., D. A. Hart, et al. (2006). "Denervation alters mRNA levels of repair-associated
genes in a rabbit medial collateral ligament injury model." J Orthop Res.
Bosse, F., P. Kury, et al. (2001). "Gene expression profiling and molecular aspects in peripheral
nerve regeneration." Restor Neurol Neurosci 19(1-2): 5-18.
Brown, I. A. (1972). "Scanning electron microscopy of human dermal fibrous tissue." J Anat
113(Pt 2): 159-68.
Chamberlain, L. J. (1998). "Influence of implant parameters on the mechanisms of peripheral
nerve regeneration."
Chamberlain, L. J., I. V. Yannas, et al. (1998). "Early peripheral nerve healing in collagen and
silicone tube implants: myofibroblasts and the cellular response." Biomaterials 19(15):
1393-403.
Chamberlain, L. J., I. V. Yannas, et al. (2000). "Connective tissue response to tubular implants
for peripheral nerve regeneration: the role of myofibroblasts." J Comp Neurol 417(4):
415-30.
Chang, A. S., I. V. Yannas, et al. (1990). "Electrophysiological study of recovery of peripheral
nerves regenerated by a collagen-glycosaminoglycan copolymer matrix." Progess in
Biomedical Polymers. New York: Plenum: 107.
Clark, R. A. F. and P. M. Henson (1988). The Molecular and cellular biology of wound repair.
New York, Plenum Press.
Cohen, I. K., R. F. Diegelmann, et al. (1992). Wound Healing: Biochemical & Clinical Aspects,
Saunders.
Colwell, A. S., M. T. Longaker, et al. (2005). "Mammalian fetal organ regeneration." Adv
Biochem Eng Biotechnol 93: 83-100.
Costigan, M., K. Befort, et al. (2004). "Replicate high-density rat genome oligonucleotide
microarrays reveal hundreds of regulated genes in the dorsal root ganglion after
peripheral nerve injury." feedback.
Darby, I. A. and T. D. Hewitson (2007). "Fibroblast differentiation in wound healing and
fibrosis." Int Rev Cytol 257: 143-79.
Dawber, R. and S. Shuster (1971). "Scanning electron microscopy of dermal fibrous tissue
networks in normal skin, solar elastosis and pseudo-xanthoma elasticum." Br J Dermatol
84(2): 130-4.
Desmouliere, A. and G. Gabbiani (1996). "The Role of the Myofibroblast in Wound Healing and
Fibrocontractive Diseases." The Molecular and Cellular Biology of Wound Repair.
Dunn, M. G., F. H. Silver, et al. (1985). "Mechanical analysis of hypertrophic scar tissue:
structural basis for apparent increased rigidity." J Invest Dermatol 84(1): 9-13.
Farrell, E., F. J. O'Brien, et al. (2006). "A collagen-glycosaminoglycan scaffold supports adult rat
mesenchymal stem cell differentiation along osteogenic and chondrogenic routes." Tissue
Eng 12(3): 459-68.
Ferdman, A. G. and I. V. Yannas (1993). "Scattering of light from histologic sections: a new
method for the analysis of connective tissue." J Invest Dermatol 100(5): 710-6.
Frank, S., M. Madlener, et al. (1996). "Transforming growth factors betal, beta2, and beta3 and
their receptors are differentially regulated during normal and impaired wound healing." J
Biol Chem 271(17): 10188-93.
Gabbiani, G. (1998). "Evolution and clinical implications of the myofibroblast concept."
Cardiovasc Res 38(3): 545-8.
Gibson, T., R. M. Kenedi, et al. (1965). "The mobile micro-architecture of dermal collagen: a
bio-engineering study." Br J Surg 52(10): 764-70.
Holbrook, K. A., P. H. Byers, et al. (1982). "The structure and function of dermal connective
tissue in normal individuals and patients with inherited connective tissue disorders." Scan
Electron Microsc(Pt 4): 1731-44.
Hynes, R. 0. (1986). "Fibronectins." Sci Am 254(6): 42-51.
Itoh, S., K. Takakuda, et al. (1999). "Synthetic collagen fibers coated with a synthetic peptide
containing the YIGSR sequence of laminin to promote peripheral nerve regeneration in
vivo." Journal of Materials Science: Materials in Medicine 10(3): 129-134.
Jiang, X., L. Xia, et al. (2008). "Otefin, a nuclear membrane protein, determines the fate of
germline stem cells in Drosophila via interaction with Smad complexes." Dev Cell 14(4):
494-506.
Kitamura, N., S. Nishinarita, et al. (2000). "Cultured human monocytes secrete fibronectin in
response to activation by proinflammatory cytokines." Clinical and Experimental
Immunology 120(1): 66-70.
Lanning, D. A., B. C. Nwomeh, et al. (1999). "TGF-B 1 alters the healing of cutaneous fetal
excisional wounds." Journal of Pediatric Surgery 34(5): 695-700.
Lau, N. C., L. P. Lim, et al. (2001). "An abundant class of tiny RNAs with probable regulatory
roles in Caenorhabditis elegans." Science 294(5543): 858-62.
Li-Korotky, H. S., P. A. Hebda, et al. (2007). "Age-dependent differential expression of
fibronectin variants in skin and airway mucosal wounds." Arch Otolaryngol Head Neck
Surg 133(9): 919-24.
Livak, K. J. and T. D. Schmittgen (2001). "Analysis of Relative Gene Expression Data Using
Real-Time Quantitative PCR and the 2- ??CT Method." Methods 25(4): 402-408.
Lundborg, G., L. B. Dahlin, et al. (1982). "Nerve regeneration in silicone chambers: influence of
gap length and of distal stump components." Exp Neurol 76(2): 361-75.
Ma, W., G. C. Horvath, et al. (2008). "Expression Patterns of SP1 and SP3 During Mouse
Spermatogenesis: SP Down-Regulation Correlates with Two Successive Promoter
Changes and Translationally Compromised Transcripts." Biol Reprod.
Madison, R. D., S. J. Archibald, et al. (1992). "Wound healing, biochemical and clinical
aspects." Peripheral nerve injury: 28,450-87.
Martin, P. (1997). "Wound healing--aiming for perfect skin regeneration." Science 276(5309):
75-81.
McDonald, J. A. (1992). "Fibronectin, a primitive matrix." The Molecular and Cellular Biology
of Wound Repair: 405-435.
Mechaly, I., S. Bourane, et al. (2006). "Gene profiling during development and after a peripheral
nerve traumatism reveals genes specifically induced by injury in dorsal root ganglia."
Molecular and Cellular Neuroscience.
Murphy, G. F., D. P. Orgill, et al. (1990). "Partial dermal regeneration is induced by
biodegradable collagen-glycosaminoglycan grafts." Lab Invest 62(3): 305-13.
Mustoe, T. A., G. F. Pierce, et al. (1991). "Growth factor-induced acceleration of tissue repair
through direct and inductive activities in a rabbit dermal ulcer model." J Clin Invest
87(2): 694-703.
Narasimhan, J., B. R. Joyce, et al. (2008). "Translation regulation by eIF2 kinases in the
development of latent cysts in toxoplasma gondii." J Biol Chem.
Nilsson, A., K. Moller, et al. (2005). "Early changes in gene expression in the dorsal root ganglia
after transection of the sciatic nerve; effects of amphiregulin and PAI-1 on regeneration."
Molecular Brain Research 136(1-2): 65-74.
Olsson, Y. (1990). "Microenvironment of the peripheral nervous system under normal and
pathological conditions." Crit Rev Neurobiol 5(3): 265-311.
Olutoye, O. O., E. J. Barone, et al. (1997). "Collagen induces cytokine release by fetal platelets:
implications in scarless healing." J Pediatr Surg 32(6): 827-30.
Olutoye, O. O., E. J. Barone, et al. (1997). "Hyaluronic acid inhibits fetal platelet function:
implications in scarless healing." J Pediatr Surg 32(7): 1037-40.
Olutoye, O. O., D. R. Yager, et al. (1996). "Lower cytokine release by fetal porcine platelets: a
possible explanation for reduced inflammation after fetal wounding." J Pediatr Surg
31(1): 91-5.
Pierce, G. F., J. E. Tarpley, et al. (1992). "Platelet-derived growth factor (BB homodimer),
transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound
healing. Neovessel and matrix formation and cessation of repair." American Journal of
Pathology 140(6): 1375-1388.
Ramirez, A. T., H. S. Soroff, et al. (1969). "Experimental wound healing in man." Surg Gynecol
Obstet 128(2): 283-93.
Rosen, J. M., V. R. Hentz, et al. (1983). "Fascicular tubulization: a cellular approach to
peripheral nerve repair." Ann Plast Surg 11(5): 397-411.
Shah, M., D. M. Foreman, et al. (1995). "Neutralization of TGFb1 and TGFb2 or exogenous
addition of TGFb3 to cutaneous wounds reduces scarring." J Cell Sci 108: 983-1002.
Soo, C., S. R. Beanes, et al. (2003). Ontogenetic Transition in Fetal Wound Transforming
Growth Factor-B Regulation Correlates with Collagen Organization, ASIP. 163: 2459-
2476.
Soo, C., F. Y. Hu, et al. (2000). Differential Expression of Fibromodulin, a Transforming
Growth Factor-B Modulator, in Fetal Skin Development and Scarless Repair, ASIP. 157:
423-433.
Sullivan, K. M., H. P. Lorenz, et al. (1995). "A model of scarless human fetal wound repair is
deficient in transforming growth factor beta." Journal of Pediatric Surgery 30(2): 198-
203.
Sunderland, S. (1990). "The anatomy and physiology of nerve injury." Muscle Nerve 13(9): 771-
84.
Sylvester, M. F., I. V. Yannas, et al. (1989). "Collagen banded fibril structure and the collagen-
platelet reaction." Thromb Res 55(1): 135-48.
Thomas, P. K. and Y. Olsson (1984). "Microscopic anatomy and function of the connective
tissue components of peripheral nerve." Peripheral Neuropathy 1: 97-120.
Troxel, K. S. (1994). Delay of skin wound contraction by porous collagen-GAG matrices,
Massachusetts Institute of Technology, Dept. of Applied Biological Sciences.
Wall, P. D. and M. Gutnick (1974). "Ongoing activity in peripheral nerves: the physiology and
pharmacology of impulses originating from a neuroma." Exp Neurol 43(3): 580-93.
Williams, L. R., N. Danielsen, et al. (1987). "Exogenous Matrix Precursors Promote Functional
Nerve Regeneration Across." The Journal of Comparative Neurology 264284: 290.
Williams, L. R., F. M. Longo, et al. (1983). "Spatial-temporal progress of peripheral nerve
regeneration within a silicone chamber: parameters for a bioassay." Journal of
comparative neurology(1911) 218(4): 460-470.
Williams, L. R., H. C. Powell, et al. (1984). "Competence of nerve tissue as distal insert
promoting nerve regeneration in a silicone chamber." Brain Res 293(2): 201-11.
Williams, L. R. and S. Varon (1985). "Modification of fibrin matrix formation in situ enhances
nerve regeneration in silicone chambers." The Journal of Comparative Neurology 231(2):
209-220.
Xu, J. and R. A. F. Clark (2000). "lntegrin Regulation in Wound Repair." Scarless Wound
Healing.
Yannas, I. V. (1990). "Biologically active analogs of the extracellular matrix." Angew. Chem 29:
20-35.
Yannas, I. V. (1995). "Tissue regeneration templates based on collagen-glycosaminoglycan
copolymers." Adv Polymer Sci 122: 219-244.
Yannas, I. V. (2001). Tissue and organ regeneration in adults. New York, Springer.
Yannas, I. V. (2005). "Similarities and differences between induced organ regeneration in adults
and early foetal regeneration." J R Soc Interface 2(5): 403-17.
Yannas Iv, B., O. Jf, et al. (1982). "EM Regeneration of skin following closure of deep wounds
with a biodegradable template." Trans Soc Biomater 5: 24.
Yannas, I. V., J. F. Burke, et al. (1975). "Correlation of in vivo collagen degradation rate with in
vitro measurements." J Biomed Mater Res 9(6): 623-8.
Yannas, I. V., J. F. Burke, et al. (1982). "Wound tissue can utilize a polymeric template to
synthesize a functional extension of skin." Science 215(4529): 174-176.
Yannas, I. V., J. F. Burke, et al. (1981). "Prompt, long-term functional replacement of skin."
Trans Am Soc Artif Intern Organs 27: 19-23.
Yannas, I. V., E. Lee, et al. (1989). "Synthesis and characterization of a model extracellular
matrix that induces partial regeneration of adult mammalian skin." Proc Natl Acad Sci U
S A 86(3): 933-7.
Yannas, I. V., D. P. Orgill, et al. (1987). "Regeneration of Sciatic Nerve Across 15 mm Gap by
Use of a Polymeric Template." Polym. Sci. Technol. Iss. Adv. Biomed. Polymer 35: 109.
Zochodne, D. W. and C. Nguyen (1997). "Angiogenesis at the site of neuroma formation in
transected peripheral nerve." J Anat 191 ( Pt 1): 23-30.
Appendix A: Compilation of Experimental Protocols
A.1 5% Collagen Tube Fabrication Protocol
Adapted from Harley, 2000
SUPPLIES
0.25 gm Type I Collagen
150 pl Glacial Acetic Acid
10 ml Degassed, Distilled Water
0.032" Dia. Stainless Steel Wire
Teflon tubing, O.D. 0.125", I.D. 0.065"
Teflon Tubing, O.D. 0.056", I.D. 0.032"
PROCEDURE
1. Degas 10 ml distilled water for 10-15 minutes
2. In centrifuge tube, mix 150 pl Glacial Acetic Acid [GAA, Mallinckrodt Chemical Co., Paris,
KY] with 850 pl degassed, distilled water [ddH20], forming 3.0M acetic acid. Draw solution
into 3 ml syringe with 22 gauge needle (Cat. No. 309574, Becton Dickinson & Co., Franklin
Lakes, NJ).
3. Weigh 0.25 g Type I Collagen (Integra Life Sciences, San Diego, CA). Place collagen into 10
ml syringe (Cat. No. 309604, Becton Dickinson & Co., Franklin Lakes, NJ) that has Parafilm
covering luer-lock end. Add 4 ml ddH20 and mix thoroughly with forceps.
Insert plunger into syringe and invert syringe, allowing collagen mixture to fall away from the
syringe tip. Remove Parafilm and mix collagen slurry by moving stopper up and down. Purge
air out from tip, bringing plunger up so that slurry comes up to the tip.
4. Slowly inject 1 ml 3.0M acetic acid into collagen, placing the needle from the 3 ml syringe
through the tip of the 10 ml syringe with collagen-water suspension. Add the 1 ml acetic acid
slowly while mixing with needle tip and pulling back on the 10 ml syringe plunger.
5. Blend slurry well until a homogenous mixture is achieved. Attach 10 ml syringe with collagen
slurry to another 10 ml syringe with a female-female Luer-lock assembly (Stainless steel luer
lock tube fitting, female luer x female luer, Cat. No. 5194k12, McMaster-Carr Supply Company,
New Brunswick, NJ), and mix by injecting collagen slurry from one syringe to another. Mix
back and forth 10-15 times, until collagen fibers begin to hydrate and solution appears uniform.
6. After mixing, remove empty syringe and Luer-lock fitting. Cover syringe tip with multiple
layers of Parafilm to seal the syringe so that the collagen does not escape during centrifugation.
Do not remove plunger, and let slurry mixture sit for 3 hours at room temperature to allow for
the collagen fibers to swell.
After 3 hours, remove plunger, but keep Parafilm over syringe tip.
7. Set Freeze-Drier to -40'C (it takes 2 1 hr for freeze-drier to reach set temperature).
8. Centrifuge the collagen slurry in the syringe in order to degas the collagen so that a
homogenous collagen slurry without any macroscopic air bubbles if formed. Place the syringe
into a 50ml conical tube, using paper towel to brace syringe along the central axis of the conical
tube. The centrifugation step may be accomplished using either of the following techniques,
depending on the availability of centrifuges:
a. High speed centrifuge with high g-force rated swinging bucket rotor:
Centrifuge the syringe in a 50 ml Falcon tube at 6000xG for 20 minutes at 25 'C.
b. Low speed with low g-force rated swinging bucket rotor:
Centrifuge the syringe in a 50 ml Falcon Tube at 4500 rpm (maximum angular velocity)
at 25°C for 60 minutes in the Heraeus Labofuge 400R in the lab. This angular velocity
translates to 3940xG.
9. Inject centrifuged (degassed) collagen slurry into Teflon and aluminum molds (Mold Diameter
3.00 mm; See Figures A.4 and A.5). Inject slurry (-0.25 ml per tube) into closed molds until
slurry is apparent on other side. Insert steel and Teflon mandrel into slurry, rotating mandrel
during insertion so as to keep the mandrel centered and to maintain a uniform deposition of
collagen throughout the mold. Cap the free end of the mandrel with the centering tube after
mandrel is fully inserted. Repeat for each mold.
The mandrel is manufactured using a stainless steel wire core (0.032" Dia., Cat. No. GWXX-
320-30, Small Parts, Inc., Miami Lakes, FL), surrounded by Teflon tubing (PTFE Tubing, Cat.
No. 06417-31, Cole-Parmer Instrument Company, Vernon Hills, IL). Teflon tubing is used at
the ends of the mandrel to space the mandrel in the center of the mold (PTFE Special Tubing,
O.D. 0.125", I.D. 0.065", Cat. No. 06407-42, Cole-Parmer Instrument Company). Both the
mandrels and spacers are autoclaved before use.
10. Place molds in freeze-drier for 1 hour. After freezing, remove the molds from the freeze-
drier and split them, gently removing the tubes. Keep the mandrels inside the tubes. Place tubes
with mandrels back into the freeze-drier (at -400 C).
11. Pull vacuum in freeze-drier until both readouts are below 100 mTorr (-30-60 minutes).
12. Raise temperature to 00 C and leave overnight under vacuum in freeze-drier (17 hours).
13. Raise temperature to 200 C and release vacuum.
14. Remove tubes (Figure A.6 for final dimensions) with mandrels from freeze-drier and place
into aluminum foil bags for storage.
ALUMINUM-TEFLON MOLD SCHEMATIC
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A.2 Dehydrothermal Crosslinking Protocol
Adapted from Harley 2000
PROCEDURE
1. Place collagen material in aluminum foil packet. Leave packet open at top.
2. Place packet in vacuum oven (Isotemp Model 201, Fisher Scientific, Boston MA) at
established set temperature. The following settings are for 5% collagen tubes:
Matrix Set Temperature Exposure Time
5 % Collagen Tubes 120 oC 48 hours
3. Turn on the vacuum. The vacuum oven should reach a final pressure of approximately -
29.7 mmHg.
4. At the end of the exposure period, turn off the vacuum and vent the chamber. Open the
vacuum door and immediately seal the aluminum foil packets. The matrix is now cross-
linked and considered sterile, so the matrix should only be handled under sterile
conditions from now on.
5. Store the matrix in a dessicator with DrieRite Absorbent (VWR Internatinal, Inc., San
Diego, California). Crosslinked matrices can remain indefinitely in a dessicator prior to
testing or use.
A.3 Sterile Procedure and Silicone Implant Assembly Protocol
Adapted from Chamberlain 1998, Spilker 2000, and Harley 2002
PROCEDURE
ONE TO TWO DAYS BEFORE IMPLANT PREPARATION:
1. Sterilize the necessary implements:
In Autoclave Bags:
Tool pack: 1 jewelers forceps
2 regular forceps
1 large forceps
1 surgical blade holder
1 needle holder
1 glass specimen jar for each silicone prosthesis (put a small piece of autoclave tape on
each jar for labeling purposes later)
1 500 mL glass bottle
Wrap in autoclave paper:
1 Teflon sheet for working area (Tape a ruler to the sheet with autoclave tape. This makes
cutting easier in the sterile environment)
2. Prepare silicone tube implants in a sterile environment by measuring 16 mm of silicone tubing
(ID: 3.1 mm, Helix Medical, LLC, Carpinteria, CA) and cut with microscissors. Flush each
twice with sterile Phosphate Buffered Saline (PBS) and place in individual glass specimen jars.
Dehydrothermally Treat (DHT):
Appropriate tubes for graft preparation (120 oC for 48 hrs).
- Silicone tubes should be placed in individual glass specimen jars.
- Collagen tubes should be placed in aluminum foil packets (n=5) as previously
described.
After DHT treatment, place specimen jars (n=5) containing silicone prosthesis in 50 mL
glass bottle), seal. Also seal aluminum foil packet containing collagen tubes immediately
after removal from vacuum oven. Place in a dessicator prior to use.
A.4 Surgical Protocol
Adapted from Chamberlain 1998, Spilker 2000, and Harley 2002
SUPPLIES
1. Order animals: Adult, female Lewis rats 150 - 200 g, from Charles River Laboratories.
Animals must arrive at least one week in advance of surgery to reduce the stress placed
on the animal due to travel.
2. Sterilize the necessary items:
1 metal bowl
gauze
1 surgical blade holder
1 micro-needle holder
1 micro-scissors
2-jewelers forceps
1 large forceps
1 large scissors
1 surgical (tenotomy) scissors
2 paper clip retractors
2 forceps
1 needle holder
animal skin staples
wooden rods (cotton swabs)
3. Ready other sterile items:
Sterile table covering sterile pen
Scalpel blades (4 # 15 blade, 1 #11 blade)) 10-0 sutures
1 bottle of PBS 4-0 sutures
iodine sponge 1 ml syringes
sterile draping 1 bottle Lidocaine, 1%
Implants (sterilized and prepared as in section A. 1)
1 bottle pentobarbital (Nembutal Sodium Solution), 50 mg/ml
small piece of wood (e.g. from tongue depressor)
4. Ready other non-sterile items:
Surgical board
4 rubber bands
rat ear tagging tool
numbered ear tags
microsurgery glasses (loops)
hair clippers
1. Weigh animal on an approximately sized balance. Record the
anesthetic dosage based on the pre-operative weight.
weight and determine
2. Anesthetize animal with injection of sodium pentobarbital (50 mg of solution per kg of
animal). Allow 10-15 minutes for anesthesia to take effect. Each animal reacts
differently to the anesthetic and in some cases, more time may be required.
PROCEDURE
3. Meanwhile, arrange the surgical area so that the table is at a comfortable level for the
surgeon, and the tool sare conveniently located.
4. The surgeon should be sterilely dressed in scrub shirt and pants, hat and mask.
5. When ready, shave the animal using the animal hair clippers from the base of the tail up
to the middle of the back. The leg receiving the prosthesis should be shaved carefully
and completely.
6. Place the animal on the surgical board in the prone position and secure the fore and hind
limbs to the board using rubber bands. The hind legs should be in 30' abduction. Place a
piece of gauze under the appropriate thigh to elevate the leg slightly.
7. Connect the animal to 02 mask for the duration of the surgical procedure.
8. Clean the shaved portion of the animal vigorously with the iodine sponge to disinfect the
area. At this point, the surgeon should put on the sterile gloves and remain sterile for the
rest of the procedure. Cut a hole in the sterile draping small enough so that only the leg is
exposed. Place the draping over the animal.
9. Using the # 15 scalpel, make a 4 cm incision along the leg of the animal. Separate the
skin from the muscle along the incision by cutting through the connective tissue with the
surgical scissors.
10. Using the surgical scissors, separate the muscles until the sciatic nerve is visible.
Carefully cut back the muscle along the skin incision line exposing the sciatic nerve.
11. Place the paper clip retractors inside the muscle to separate the wound edges.
Anesthetize the nerve by placing a few drops of Lidocaine directly on the area. Cut away
the fascia surrounding the sciatic nerve carefully so that the nerve is free from constraint.
12. Place the sterile wood piece underneath the nerve and carefully transect the nerve
midway between the proximal nerve trunk and the distal bifurcation using the scalpel.
Measure the prosthesis and make a mark on the nerve stumps 3 mm from each end. If
necessary, trim prosthesis to appropriate length using microscissors.
13. Place the tube in the gap and insert the proximal nerve stump 3 mm into the tube end, as
marked. Secure the nerve in place by using two 10-0 sutures which travel through the
epineurium and then through the tube. Inject enough sterile PBS into proximal end of
prosthesis to fill the device using the 1 cc syringe. Tie the sutures with four single knots.
Insert the distal nerve end 3 mm into the other end of the tube and secure in the same
manner.
14. Remove the paper clip retractors and close the muscle layer using three 4-0 sutures.
Close the skin using skin staples.
15. Place the animals on heating pads with 02 masks and monitor until they are mobile.
A.5 Post-Operative Care and Supervision Protocol
Adapted from Spilker 2000, Harley 2002
SUPPLIES
Buprenorphine, 0.15 mg/ml
1 ml Syringe
27 gauge needle
PROCEDURE
1. Monitor rats immediately following surgery. Analgesic is to be started immediately
following surgery while the rat is still under anesthesia. Inject 0.1 ml 0.15 mg/ml
Buprenorphine (approximately 0.1 mg/kg, Cat No. 40182C, Lyphomed, Deerfield, IL)
subcutaneously and continue for a minimum of 48 hours, then as often as needed. Inject
50 mg/day of Cefazolin subcutaneously and continue once daily for 3 days. For
hydration, make a one-time injection of 1 mL sterile PBS immediately following surgery.
2. Place rats into individual cages for first week following surgery. Place food onto floor of
cage for the rat immediately following surgery.
3. Repeat analgesic and antibiotic injections for 48 hrs following surgery. Continue to
monitor eating and drinking and general condition of animals.
4. Monitor rats twice a day for one week following surgery. At 7 days post-operatively,
combine rats two to a cage and switch to observing once a day for the length of the
experiment.
A.6 Animal Sacrifice and Tissue Processing Protocol
Soller 2007
EQUIPMENT
Surgical instruments
Insulated Container with Liquid Nitrogen
Rectangular R-40 Peel-A-Way@ Embedding Molds (PolySciences, Inc., Warrington, PA)
OCT Embedding medium
Tissue marker
Freezer packs
Portable Cooler
SACRIFICE PROCEDURE
1. Sacrifice animals by placing in carbon dioxide chamber for 3-5 minutes.
2. Open the original wound with a # 15 scalpel blade. The wound can be located by
identifying the dermal scar or skin staples.
3. Open the fascia and muscle to locate the tube implant and adjacent nerve stumps.
4. Photograph the experimental wound space in situ prior to removing the implant. Note
connective tissue response.
5. Remove the entire tube implant as well as at least 5 mm of proximal and distal nerve
tissue. Mark the proximal stump with the tissue marker
6. Photograph the explant on the sterile surgery board to capture the gross morphology.
TISSUE PROCESSING PROCEDURE
1. Fill the bottom of the Rectangular Embedding mold with OCT.
2. Carefully place explant (nerve stumps + prosthesis) on top of OCT layer as flatly as
possible. Maintain sample orientation by labeling the side of the mold that is closest to
the proximal nerve stump.
3. Slowly cover the explant with OCT until the mold is mostly filled and the sample is
completely covered. Mold dimensions are 22mm wide x 40mm long x 20mm deep.
4. Using forceps, carefully lower mold into liquid nitrogen and allow the OCT to freeze.
Do not completely immerse the mold to avoid quenching. Wait until freezing is complete
before moving mold to cooler filled with freezer packs.
5. Store OCT-embedded samples in their molds in a -800 C freezer for future analysis.
A.7 RNA Extraction using ARCTURUS PicoPure RNA Isolation Kit
1. Obtain samples and thaw them if frozen. Spin at 14,000 rpm for 1 min.
2. Transfer the supernatant to new temporary 1.5ml E-tubes and spin again at 14,000
rpm for 1 min.
3. Get and label 1 purification column filter per sample, add 250tl condition buffer onto
them, and incubate for 5 min. at room temperature.
4. Centrifuge the columns at 13,000 rpm for 1 min.
5. Add 30pl of 70% ethanol to the cell extract and mix in step 1 by pipetting up and
down. DO NOT CENTRIFUGE! Ethanol can also be found in the PCR kit. Ethanol
precipitates out DNA & RNA
6. Pipette the cell extract and ethanol mixture to the pre-conditioned column and spin
for 2 min. at 900 rpm to bind RNA, immediately followed by spin at 13,000 rpm for
30 sec.
7. Add 100 tl wash buffer 1 to the column and spin for 1 min at 9000 rpm.
8. Get Qiagen RNase-free DNAse Set from the fridge under the microwave (come in 10
[l or 20 pl aliquots - need 10 pl per sample) and Buffer RDD DNA digest buffer
from the upper right corner of the glass door VWR fridge in a grey box.
9. Add 70 tl of Buffer RDD DNA Digest buffer to each 10 [l aliquot of DNAse. This
will give you a total of 80 pl of .34U/pl DNase I. In total you need 80 pl of .34U/pl
DNAse I per sample.
10. Add 40pl of 0.34u/tl DNase I (QIAGEN) to the column and spin at 900 rpm for 1
min. then add another 40l DNase I to the column and incubate at room temperature
for 15 min.
11. Add 40ýtl wash buffer 1 to the column and spin for 15 sec. at 9000 rpm.
12. Add 100pl wash buffer 2 to the column and spin for 1 min. at 9000 rpm.
13. Add 1001l wash buffer 2 to the column and spin for 3 min. at 14,000 rpm.
14. Get new .5 mL E-tubes (1 per sample) and cut off the tops. Transfer the column to
new 0.5 ml microcentrifuge tubes (not the ones from the kit - use E-tubes from big
bag in drawer b/c they are stronger).
15. Add 16 gl elution buffer to the column and incubate for 1 min at room temperature.
16. Spin the column for 1 min at 3000 rpm and spin for 1 min at 14,000 rpm to elute
RNA. The isolated RNA is now ready for RT-PCR.
A.8 Reverse Transcription using Invitrogen SuperScript III First-Strand
Synthesis System for RT-PCR
All of the solutions used in these mixtures can be found in the red invitrogen box in the fridge
underneath the microwave. Some of the solutions take a while to thaw, so take out a little bit in
advance (the RNase OUT, SS III RT, and RNase H should not be frozen solid though).
Materials for each preparation are listed below
Preparation of RNA/primer mix: Prepare cDNA synthesis mix
16 pl total RNA 4 tl 10x RT buffer
2 pl 50 ng/ml random hexamers 8 il 25 mM MgCl 2
2 pl 10-mM dNTP mix 4 pl 0.1 M DTT
2 al 40 U/pl RNase OUT
2 pl 200 U/pl SuperScript III RT
1. Obtain 1 PCR tube (small tubes with rounded tops) per sample and label them (label caps
and tops of sides - bottom of sides smudges)
2. Prepare the primer mix by adding together equal amounts of the random hexamers and
the dNTP mix in a .5 mL E-tube - 24l per sample of each and an extra 24l of each for
every 5 samples to account for pipette error (e.g. for 5 samples, add 12 pl of each).
Vortex to mix, spin if necessary.
3. Add 4 pl of the primer mix to each PCR tube
4. Add 16 pl of the RNA to each PCR tube - remember to change tips!
5. Vortex and spin each of the PCR tubes and incubate at 65 'C for 5 min in the PXE 0.2
Thermal Cycler (put it on manual and set the temperature to 65).
6. After incubation, place on ice for at least 1 min. Once you take it off the ice, if there is
condensation, spin again.
7. Mix together the amounts of the materials listed above for the cDNA synthesis mix in a
.5 mL E-tube. The amounts listed are per sample - therefore, multiply the number above
by the number of samples and add that volume to the E-tube. For every 5 samples, add
the amount of half an extra sample to account for pipette error (e.g. for 5 samples, add
5.5*4 tpl of 10Ox RT buffer = 22 pl of O1x RT buffer, etc.). This should come out so that
you have equal volumes of cDNA synthesis mix and RNA/primer mix
8. Add equal volume of cDNA synthesis mix (20 tpl) to RNA/primer mix - there should be
20 pl of RNA/primer mix, so we add 20 pl of cDNA. Be sure to change tips in between
samples.
9. Vortex and spin each sample.
10. Incubate as follows (PCR program A 02 B)
Manually set temp to 25 'C and check before running program. Also, in program, set
number of samples to the number of samples being run, and sample volume to 40 l1
25oC for 10 min
50'C for 50 min
85oC for 5 min, then chill on ice for at least 1 minute to prevent evaporation. Spin
down condensation afterwards
Add 2 pl RNase H to the reaction mix - vortex and spin - and incubate at 370 C for 20 min. This
is to get rid of RNA that is bound to cDNA. The cDNA is now ready for PCR or store at -200 C.
A.9 Real Time PCR Protocol for Checking cDNA
1. Collect sample from freezer and put on ice
2. In new small tubes (for temporary use only), label and add .5 jl of sample and 2 pl of
H20. Vortex and spin. The H20 is found in a 25 ml tube in the Styrofoam rack to the
left of the PCR machine.
The Applied Biosystem's Taqman Universal PCR Master Mix (2x) has everything you need
except Applied Biosystem's Taqman Gene Expression Assays (20x). We want a final
volume of 25 pl with a final concentration of Ix. This will include the master mix, probe,
water, and 1 pl of the sample. For checking cDNA, we need 10 assays, which means 250 pl
total.
3. For 10 assays, add, vortex, spin (remember to change tips) the following:
125 pl of 2x master mix
12.5 pl of 20x GAP assay
102.5 pl of water
The 2x master mix is found in the fridge to the right of the fume hood in a white Taqman box
in the upper left comer of the fridge. The 20x GAP probe is in the fridge beneath the
microwave
4. Obtain and mark one side of the row of tubes to mark it as the first of the row. Tubes
are located in the top drawer to the left of the PCR machine first box on the right.
The caps for these tube rows are located in the box in the back right comer of the
drawer.
5. Add 24 pl of master mixture to each of the tubes.
6. Add 1 pl of each sample to the corresponding tube, and mark them down on the paper
chart, and place caps on the tubes
7. Vortex and spin - remember to add balance when spinning and be sure to get rid of
all bubbles.
8. Now go to computer and set up the software (Applied Biosystem's 7300 Real-Time
PCR System software)
9. Go to File -> New
10. In new document, make sure assay is set to "Standard Curve (Absolute
Quantitation). Then, click next.
11. Go to detectors and highlight r-GAPDM (housekeeping gene) & click add, then click
next
12. Set up the sample plate - highlight desired cells and click "use" box next to the r-
GAPDH gene, then click finish.
13. In chart, select cells and label/name them by double clicking on the corresponding
cell.
14. To open loading tray, push only where the circular indentation is. Load cells (always
load along columns!)
15. Go to the instrument tab and change sample volume to 25 pl
16. SAVE! For test filename is test, month, date, yea - e.g. test121406, then click start.
A.10 Real Time PCR Protocol
One nerve (5 samples) will fit on a single 96-well PCR plate
1. Obtain 2x master mix from white fridge next to the fume hood on the left side of the
upper shelf in the white Taqman box.
2. Obtain 20x primers from the fridge underneath the microwave in the boxes labeled
for rat primers and thaw at room temperature.
3. Obtain sterile water from the Styrofoam rack to the left of the PCR machine.
4. Create a master mix for each gene (6 total) by combining the following in a 1.5 ml
Eppendorf tube:
212.5 pl of 2x master mix
21.25 pl of particular 20x primer
174.25 pl of sterile water
This will give you enough master mix for 17 samples - we only need 15, but add 2
for pipette error.
5. Vortex and spin the 6 master mixes.
6. Obtain a PCR 96-well plate from the top drawer beneath the PCR machine as well as
a black holder from the same drawer.
7. Fill out paper chart according to the desired arrangement of samples on the 96-well
PCR plate.
8. Add 24 p1 of specified master mix according to the arrangement decided on the chart
- use parafilm to cover rows that are not in use to prevent contamination.
9. Obtain samples from freezer and allow them to thaw.
10. Add 1 pl of each sample to specified wells in the 96-well plate according to the
layout on the chart. Remember to use parafilm to cover cells that are not in use.
NOTE: it is best to use a new box of 10 pl pipette tips since the arrangement of tips in
the box is exactly the same as the arrangement of wells in the 96-well plate. This
helps keep track of which cells have been loaded already.
11. Place a membrane sticker over the top of the plate (stickers in box in PCR drawer),
and use grey rubber thing to smooth it out. Rip off edges, and smooth them down
with the grey rubber thing.
12. Vortex the entire plate at the agitator to the right of the mini-centrifuge.
13. Centrifuge the plate in the big centrifuge for about 5 minutes - place in holder, close
lid, flip lock switch to locked position, and turn dial to -5 minutes.
14. Go to computer and set up the software (Applied Biosystem's 7300 Real-Time PCR
System software)
15. File, new document - select relative quantitation plate, then click Next
16. Select the rat genes (6 of them) and click add, then click Next
17. Set up the plate/cells according to their arrangement in the plate, and change the
GAPDH from target to ENDO under the task region.
18. Click finish and then proceed to name the cells according to the samples
19. Go to the instrument tab and set the total volume to 25 pl
20. Save - filename NRG where is the date (e.g. NRG011807)
21. Load array plate (ensure proper orientation) and click start. PCR machine takes - 2
hours to run.
Appendix B: Raw PCR Data
RQ RQ
0.909 0.118
2.059
Sample
D1S1
D1S2
D1S3
D1S4
D1S5
D3S1
D3S2
D3S3
D3S4
D3S5
D7S1
D7S2
D7S3
D7S4
D7S5
D14S1
D14S2
D14S3
D14S4
D14S5
D21S1
D21S2
D21S3
D21S4
D21S5
D1C1
D1C2
D1C3
D1C4
D1C5
D3C1
D3C2
D3C3
D3C4
D3C5
D7C1
D7C2
D7C3
D7C4
D7C5
D14C1
D14C2
D14C3
RQ
1.000
12.978
4.601
7.071
1.717
0.424
2.213
0.913
0.999
2.971
2.723
1.410
0.997
1.810
0.812
4.019
0.438
5.606
3.538
0.789
0.748
1.609
1.216
1.188
1.089
0.971
0.450
2.463
0.761
0.900
0.343
1.042
1.504
0.631
0.216
0.946
0.360
RQ
0.126
0.814
3.299
2.511
1.721
1.384
2.852
2.042
3.269
2.218
2.546
1.648
2.906
1.716
2.272
0.815
2.299
1.169
1.087
0.345
0.434
4.682
5.337
0.745
1.848
1.360
1.495
1.549
1.290
0.969
0.203
0.109
0.445
0.693
0.452
1.138
2.313
1.478
RQ
1.652
3.719
2.740
2.192
2.264
0.332
1.725
1.048
1.045
0.171
0.606
0.798
2.173
1.857
4.569
0.852
1.538
0.150
0.320
0.764
0.459
1.888
2.670
2.894
0.773
0.295
0.938
0.606
0.825
0.957
0.171
0.917
0.978
0.796
0.146
0.281
0.486
0.806
RQ
1.709
0.579
0.857
1.127
0.029
0.412
0.549
0.372
1.292
0.899
1.641
0.971
1.413
1.402
1.577
1.612
0.799
1.149
0.901
0.536
0.090
0.308
0.901
0.924
0.052
0.374
0.143
0.490
0.250
0.213
0.183
0.501
0.258
0.386
0.326
0.623
1.461
2.646
2.896
0.211
1.554
3.748
1.714
1.455
1.603
2.291
1.024
0.651
0.852
1.442
3.354
3.458
1.753
4.711
1.477
1.078
0.722
0.355
1.193
0.389
0.095
0.151
0.401
0.598
0.136
0.131
0.305
0.301
0.646
0.462
0.900
0.463
RQ
1.895
2.486
2.546
0.902
0 213
2.478
1.796
0.627
A Q925
2.967
0.261
2.643
0.394
2.683
0.670
1.742
1.223
1.533
1.130
0.413
0.246
1.035
1.492
1.671
0.909
0.801
1.177
0.809
2.113
0.674
0.467
0.403
3.766
2.107
2.900
2.547
1.581
0.935
0.144
0.785
0.122
2.072
0.751
0.095
1.668
0.925
2.085
0.263
2.990
1.669
RQ
2.370
3.227
1.806
2.719
4.196
3.497
2.359
2.918
6.054
2.734
1.649
2.599
2.868
4.039
2.221
3.027
5.177
11.066
1.283
2.780
2.102
1.444
1.724
2.450
2.706
3.918
4.870
4.398
3.648
2.938
0.908
1.963
0.707
1.613
0.576
0.584
2.380
2.521
2.018
0.208
1.099
1.228
RQ
0.505
2.610
3.224
2.500
1.069
2.977
1.588
0.137
0.940
1.813
2.213
1.360
0.639
0.685
4.685
0.793
0.408
0.230
1.171
1.035
2.154
0.625
0.416
0.428
0.302
0.000
0.000
0.000
0.000
0.000
0.203
0.690
0.835
0.773
0.986
0.410
1.482
2.320
2.542
0.138
0.100
4.087
1.899 1.137 1.157 1.331
B.1 Fibronectin
P-value
0.973
0.596
0.976
0.296
n qnr
0.474
n 1i1
RQ
2.154
0.990
0.473
0.992
0.349
2.433
1.376
0.613
0.728
2.801
3.329
0.771
1.028
1.540
4.604
3.313
0.758
1.290
4.078
1.223
2.344
1.602
1.361
0.836
3.065
0.000
0.000
0.000
0.000
0.000
0.176
0.496
0.132
0.132
0.091
0.081
0.299
0.174
0.321
0.157
1.118
0.856
1.552
1.045
1.821
0.880
2.147
0.890 0.358 3.378
1.535
1.537
0.955
2.444
0.739
6.769
7.047
4.850
0.788
0.000
0.000
0.000
0.000
0.000
0.403
2.900
2.149
1.513
3.453
0.154
0.079
0.384
0.258
0.476
1.688
1.280
0.241
0.316
0.173
0.674
0.294
0.231
0.412
0.767
0.868
0.967
0.526
0.317
jd · a
0.766 1.046 1.720 0.578 0.632 1.744
0.558 0.605 0.591 0.562 0.427 2.388
0.292
0.064
2.428
6.404
1.947
D14C4
D14C5
D21C1
D21C2
D21C3
D21C4
D21C5
Sample
D1 S Avg
D3S Avg
D7S Avg
D14S Avg
D21S Avg
D1C Avg
D3C Avg
D7C Avg
D14C Avg
D21C Avg
D1S 1&5
D3S 1&5
D7S 1&5
D14S 1&5
D21S 1&5
D1C 1&5
D3C 1&5
D7C 1&5
D14C 1&5
D21C 1&5
D1S 2-4
D3S 2-4
D7S 2-4
D14S 2-4
D21S 2-4
D1C 2-4
D3C 2-4
D7C 2-4
D14C 2-4
RQ
5.474
1.504
1.550
2.878
0.000
1.170
1.109
0.880
0.569
0.000
1.359
1.698
1.767
2.404
0.000
0.919
0.935
0.487
0.387
0.000
8.217
1.375
1.406
3.194
0.000
1.338
1.225
1.273
0.691
RQ
1.694
2.353
2.218
1.143
0.000
2.609
1.333
0.380
1.316
0.000
0.923
1.801
2.409
0.580
0.000
1.141
1.165
0.327
0.871
0.000
2.208
2.721
2.090
1.518
0.000
3.588
1.444
0.416
1.613
RQ
2.513
0.864
2.001
0.725
0.000
1.737
0.724
0.601
0.777
0.000
1.958
0.251
2.588
0.808
0.000
0.616
0.626
0.158
0.436
0.000
2.884
1.273
1.609
0.670
0.000
2.484
0.790
0.897
1.004
RQ
0.860
0.705
1.401
0.999
0.000
0.455
0.294
0.331
0.823
0.000
0.869
0.655
1.609
1.074
0.000
0.071
0.294
0.255
0.593
0.000
0.854
0.738
1.262
0.950
0.000
0.711
0.294
0.382
0.976
RQ
1.665
2.015
1.252
2.951
0.000
0.747
0.276
0.369
0.556
0.000
0.560
1.579
1.866
2.416
0.000
0.734
0.116
0.296
0.663
0.000
2.771
2.305
0.842
3.307
0.000
0.756
0.383
0.417
0.484
D21C 2-4 0.000 0.000 0.000 0.000 0.000 2.966 0.666 2.576 1.441 1.441
RQ
1.303
1.570
0.863
1.074
1.485
2.014
0.775
1.007
2.434
2.227
0.256
2.108
1.311
1.240
2.939
1.521
0.447
0.179
2.689
1.119
2.351
1.212
0.564
0.962
0.515
2.343
0.993
1.559
2.263
1.697
1.298
0.307
0.425
0.204
1.368
2.304
RQ
2.864
3.512
2.675
4.667
2.085
3.954
1.153
1.542
1.444
0.922
3.283
3.115
1.935
2.904
2.404
3.428
0.742
0.396
1.198
1.305
2.584
3.777
3.169
5.842
1.873
4.305
1.428
2.306
1.608
1.069
0.434
3.458
5.673
3.769
1.301
1.086
RQ
1.982
1.491
1.917
0.727
0.785
0.000
0.698
1.378
1.365
3.057
0.787
2.395
3.449
0.914
1.228
0.000
0.595
0.274
0.267
2.272
0.818
0.906
1.113
2.042
1.267
0.000
0.253
0.264
1.117
1.338
1.489
0.599
3.240
2.130
2.359
0.595
RQ
0.992
1.590
2.254
2.132
1.842
0.000
0.205
0.206
1.192
1.785
1.251
2.617
3.967
2.268
2.705
0.000
0.134
0.119
1.303
0.597
1.978
2.449
1.473
1.342
6.222
0.000
2.187
0.240
1.592
2.166
1.130
3.546
0.347
2.190
1.788
0.676
RQ
1.608
2.558
1.112
1.723
4.039
0.000
2.084
0.270
1.519
1.709
1.054
2.722
0.571
2.295
0.764
0.000
1.928
0.315
1.409
2.111
1.978
2.449
1.473
1.342
6.222
0.000
2.187
0.240
1.592
P-value
0.661
0.008
0.000
0.128
0.872
0.957
0.002
0.000
0.059
0.350
0.628
0.049
0.041
0.138
0.317
B.2 TGF-I31
Sample RQ RQ RQ RQ RQ RQ RQ RQ RQ RQ P-value
D1S1 0.086 0.023 0.112 0.182 0.073 0.122 0.194 0.036 0.152 0.170 0.016
D1S2 0.478 0.084 0.183 0.068 0.249 0.394 0.293 0.249 0.259 0.521
D1S3 0.503 0.218 0.183 0.084 0.241 0.377 0.481 0.268 0.178 0.837
D1S4 0.464 0.245 0.281 0.114 0.203 0.277 0.291 0.344 0.126 0.093 0.840
D1S5 0.136 0.149 0.163 0.049 0.085 0.130 0.370 0.050 0.080 0.037 0.142
D3S1 0.782 0.139 0.066 0.171 0.130 0.121 0.175 0.203 0.160 0.229 0.835
D3S2 0.537 0.140 0.323 0.122 0.257 0.146 0.113 0.133 0.470 0.200 0.670
D3S3 1.696 0.130 0.452 0.136 0.281 0.278 0.149 0.167 0.115 0.614 0.449
D3S4 0.171 0.218 0.338 0.412 0.176 0.122 0.215 0.143 0.078 0.298 0.355
D3S5 0.441 0.248 0.108 0.132 0.165 0.157 0.117 0.223 0.269 0.250 0.398
D7S1 0.201 0.376 0.138 0.216 0.396 0.154 0.192 0.147 0.301 0.062 0.063
D7S2 0.152 0.202 0.205 0.140 0.271 0.051 0.185 0.094 0.094 0.304 0.651
D7S3 0.531 0.463 0.374 0.207 0.393 0.243 0.286 0.497 0.620 0.340 0.003
D7S4 0.233 0.380 0.226 0.202 0.357 0.163 0.165 0.187 0.201 0.359 0.901
D7S5 0.109 0.269 0.674 0.328 0.233 0.232 0.284 0.312 0.352 0.082 0.025
D14S1 0.341 0.371 0.152 0.324 0.377 0.326 0.387 0.110 0.415 0.285 0.985
D14S2 0.045 0.463 0.425 0.182 0.413 0.195 0.309 0.608 0.303 0.326 0.924
D14S3 1.052 0.363 0.077 0.469 0.399 0.298 0.448 0.539 0.207 0.185 0.141
D14S4 0.754 0.367 0.129 0.302 0.273 0.485 0.360 0.264 0.287 0.245 0.514
D14S5 0.027 0.179 0.137 0.233 0.470 0.259 0.554 0.245 0.339 0.378 0.707
D21S1 0.327 0.595 0.275 0.273 0.081 0.410
D21S2 0.285 0.398 0.162 0.195 0.308 0.275
D21S3 0.175 0.459 0.177 0.162 0.403 0.726
D21S4 0.205 0.413 0.295 0.255 0.522 0.884
D21S5 0.524 0.178 0.313 0.439 0.379 0.785
D1C1 0.220 0.032 0.200 0.263 0.213 0.257 0.288 0.000 0.000 0.000
D1C2 0.279 0.457 0.313 0.184 0.127 0.341 0.339 0.000 0.000 0.000
D1C3 0.183 0.569 0.416 0.199 0.089 0.322 0.305 0.000 0.000 0.000
D1C4 0.238 0.043 0.428 0.195 0.191 0.224 0.307 0.000 0.000 0.000
D1C5 0.265 0.215 0.228 0.071 0.109 0.204 0.255 0.000 0.000 0.000
D3C1 0.304 0.422 0.185 0.100 0.266 0.161 0.211 0.074 0.084 0.141
D3C2 0.240 0.374 0.149 0.090 0.113 0.242 0.298 0.298 0.142 0.455
D3C3 0.415 0.443 0.138 0.201 0.231 0.091 0.268 0.381 0.147 0.463
D3C4 0.294 0.347 0.184 0.176 0.174 0.282 0.380 0.272 0.114 0.464
D3C5 0.348 0.235 0.324 0.186 0.230 0.205 0.209 0.376 0.070 0.498
D7C1 0.079 0.132 0.111 0.165 0.284 0.077 0.121 0.178 0.124 0.140
D7C2 0.074 0.076 0.270 0.263 0.164 0.292 0.336 0.256 0.056 0.104
D7C3 0.086 0.146 0.297 0.170 0.220 0.227 0.404 0.323 0.027 0.160
D7C4 0.256 0.218 0.195 0.226 0.365 0.300 0.333 0.049 0.331
D7C5 0.069 0.290 0.068 0.167 0.181 0.104 0.121 0.057 0.144 0.272
D14C1 0.211 0.544 0.246 0.382 0.297 0.417 0.254 0.064 0.284 0.379
D14C2 0.447 0.513 0.179 0.309 0.169 0.322 0.326 0.413 0.306 0.225
D14C3 0.107 0.335 0.193 0.281 0.245 0.294 0.382 0.336 0.282 0.215
D14C4 0.576 0.379 0.382 0.266 0.327 0.349 0.390 0.425 0.417 0.352
D14C5 0.193 0.222 0.339 0.262 0.457 0.475 0.302 0.287 0.279 0.227
D21C1 0.077 0.051 0.424 0.070 0.410
0.070 0.076 0.292 0.295 0.231D21C2
D21C3
D21C4
D21C5
Sample
D1 S Avg
D3S Avg
D7S Avg
D14S Avg
D21S Avg
D1C Avg
D3C Avg
D7C Avg
D14C Avg
D21C Avg
D1S 1&5
D3S 1&5
D7S 1&5
D14S 1&5
D21S 1&5
D1C 1&5
D3C 1&5
D7C 1&5
D14C 1&5
D21C 1&5
D1S 2-4
D3S 2-4
D7S 2-4
D14S 2-4
D21S 2-4
D1C 2-4
D3C 2-4
D7C 2-4
D14C 2-4
D21C 2-4
RQ
0.333
0.725
0.245
0.444
0.000
0.237
0.320
0.077
0.307
0.000
0.111
0.612
0.155
0.184
0.000
0.242
0.326
0.074
0.202
0.000
0.482
0.801
0.305
0.617
0.000
0.233
0.317
0.080
0.377
0.000
RQ
0.144
0.175
0.338
0.349
0.000
0.263
0.364
0.180
0.399
0.000
0.086
0.193
0.323
0.275
0.000
0.123
0.329
0.211
0.383
0.000
0.182
0.163
0.348
0.398
0.000
0.356
0.388
0.159
0.409
0.000
RQ
0.184
0.257
0.323
0.184
0.000
0.317
0.196
0.193
0.268
0.000
0.137
0.087
0.406
0.145
0.000
0.214
0.254
0.090
0.292
0.000
0.216
0.371
0.268
0.210
0.000
0.385
0.157
0.262
0.251
0.000
RQ
0.099
0.194
0.219
0.302
0.000
0.183
0.151
0.192
0.300
0.000
0.115
0.151
0.272
0.279
0.000
0.167
0.143
0.166
0.322
0.000
0.089
0.223
0.183
0.318
0.000
0.193
0.156
0.209
0.285
0.000
RQ
0.151
0.202
0.330
0.386
0.000
0.146
0.203
0.215
0.299
0.000
0.079
0.148
0.314
0.423
0.000
0.161
0.248
0.232
0.377
0.000
0.222
0.238
0.341
0.362
0.000
0.136
0.173
0.203
0.247
0.000
0.412
0.484
0.499
RQ
0.195
0.165
0.169
0.312
0.303
0.270
0.196
0.213
0.371
0.308
0.126
0.139
0.193
0.292
0.426
0.231
0.183
0.090
0.446
0.288
0.263
0.182
0.152
0.326
0.222
0.296
0.205
0.294
0.322
0.322
0.134
0.341
0.442
RQ
0.325
0.154
0.222
0.412
0.409
0.299
0.273
0.256
0.331
0.209
0.282
0.146
0.238
0.471
0.387
0.272
0.210
0.121
0.278
0.247
0.354
0.159
0.212
0.372
0.423
0.317
0.315
0.347
0.366
0.184
0.496
0.227
0.369
RQ
0.241
0.174
0.247
0.353
0.244
0.000
0.280
0.229
0.305
0.361
0.043
0.213
0.229
0.177
0.294
0.000
0.225
0.118
0.175
0.396
0.214
0.221
0.305
0.266
0.204
0.000
0.134
0.044
0.335
0.288
0.231
0.338
0.144
RQ
0.175
0.218
0.314
0.310
0.265
0.000
0.111
0.080
0.314
0.215
0.116
0.214
0.326
0.377
0.356
0.000
0.077
0.134
0.281
0.107
0.177
0.370
0.335
0.252
0.411
0.000
0.461
0.198
0.264
0.284
0.269
0.352
0.257
RQ
0.147
0.318
0.229
0.284
0.339
0.000
0.404
0.201
0.279
0.304
0.103
0.240
0.072
0.331
0.230
0.000
0.319
0.206
0.303
0.334
0.177
0.370
0.335
0.252
0.411
0.000
0.461
0.198
0.264
0.284
P-value
0.219
0.893
0.007
0.543
0.458
0.013
0.751
0.007
0.807
0.314
0.484
0.654
0.045
0.544
0.292
B.3 TGF-32
Sample
D1S1
D1S2
D1S3
D1S4
D1S5
D3S1
D3S2
D3S3
D3S4
D3S5
D7S1
D7S2
D7S3
D7S4
D7S5
D14S1
D14S2
D14S3
D14S4
D14S5
D21S1
D21S2
D21S3
D21S4
D21S5
D1C1
D1C2
D1C3
D1C4
D1C5
D3C1
D3C2
D3C3
D3C4
D3C5
D7C1
D7C2
D7C3
D7C4
D7C5
D14C1
D14C2
D14C3
D14C4
D14C5
D21C1
R Q R Q R Q
0.00005 0.00016 0.00016
0.00006 0.00018 0.00060
0.00022 0.00006 0.00043
0.00044 0.00025 0.00036
0.00025 0.00011 0.00021
0.00000 0.00055 0.00013
0.00225 0.00024 0.00033
0.00169 0.00000 0.00061
0.00044 0.00045 0.00100
0.00131 0.00049 0.00044
0.00079 0.00020 0.00027
0.00040 0.00084 0.00018
0.00047 0.00095 0.00019
0.00033 0.00112 0.00022
0.00033 0.00108 0.00044
0.00233 0.00068 0.00025
0.00018 0.00092 0.00004
0.00095 0.00088 0.00000
0.00068 0.00060 0.00000
0.00019 0.00069 0.00024
0.00012 0.00008 0.00027
0.00018 0.00012 0.00007
0.00021 0.00017 0.00015
0.00081 0.00012 0.00011
0.00013 0.00024 0.00002
0.00000 0.00023 0.00719
0.00017 0.00022 0.00000
0.00084 0.00027 0.00051
0.00142 0.00027 0.00030
0.00084 0.00059 0.00033
0.00202 0.00013 0.00007
0.00033 0.00009 0.00042
0.00011 0.00016 0.00038
0.00035 0.00032
0.00119 0.00000 0.00015
0.00000 0.00203 0.00017
0.00000 0.00074 0.00028
0.00025 0.00041 0.00017
0.00000 0.00053 0.00038
0.00000 0.00000 0.00053
R Q R Q R Q
0,00022 0.00004 0.00000
0.00004 0.00010
0,00004 0.00028
0.00007 0.00084 0.00013
0.00000 0,00020 0.00016
0.00000 0.00100 0.00025
0.00009 0.00024 0.00002
0.00009 0.00033 0.00000
0.00050 0.00011 0.00007
0.00035 0.00017 0.00029
0.00041 0.00013 0.00088
0.00007 0.00024 0.00024
0.00000 0,00052 0.00038
0.00000 0.00039 0.00036
0.00023 0.00068 0.00064
0.00049 0.00071 0.00050
0.00006 0.00030 0.00012
0.00005 0.00010 0.00009
0.00003 0.00012 0.00028
0.00013 0.00103 0.00042
0,00113
0.00118
0.00072
0.00115
0.00309
0.00000 0.00015 0.00017
0.00000 0.00076 0.00027
0.00004 0.00000 0.00034
0.00003 0.00008 0.00024
0.00000 0.00005 0.00019
0.00015 0.00000 0.00000
0.00000 0.00016 0.00013
0.00008 0.00029 0.00052
0.00028 0.00021 0.00051
0.00016 0.00149 0.00018
0.00000 0.00024 0.00000
0.00018 0.00012 0.00043
0.00009 0.00000 0.00025
0.00010 0.00010 0.00053
0.00000 0.00155 0.00012
0.00098 0.00000 0.00072
0.00026 0.00011 0.00056
0.00024 0.00017 0.00080
0.00016 0.00061 0.00070
0.00013 0.00079 0.00176
0.00027
R Q R Q
0.00023 0.00008
0.00019 0.00036
0.00033 0.00035
0.00021 0.00047
0.00028 0.00015
0.00039 0.00026
0.00010 0.00007
0.00015 0.00000
0.00012 0.00021
0.00044 0.00045
0.00052 0.00067
0.00045 0.00027
0.00044 0.00026
0.00041 0.00045
0.00063 0.00070
0.00111 0.00087
0.00069 0.00175
0.00053 0.00108
0.00051 0.00042
0.00060 0.00084
0.00206 0.00175
0.00171 0.00191
0.00190 0.00133
0.00134 0.00206
0.00045 0.00201
0.00015 0.00000
0.00037 0.00000
0.00045 0.00000
0.00031 0.00000
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0.00033 0.00016
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0.00016 0.00000
0.00021 0.00044
0.00025 0.00049
0.00029 0.00055
0.00007 0.00000
0.00061 0.00000
0.00097 0.00063
0.00108 0.00038
0.00084 0.00067
0.00076 0.00078
0.00195 0.00100
R Q
0.00019
0.00057
0.00000
0.00000
0.00013
0.00053
0.00141
0.00005
0.00005
0.00022
0.00033
0.00047
0.00022
0.00051
0.00034
0.00047
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0.00102
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0.00011
0.00012
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0.00049
0.00042
0.00043
0.00077
0.00261
0.00113
R Q P-value
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0.00000 0.882
0.00000 0.965
0.00000 0.804
0.00026 0.259
0.00070 0.408
0.00069 0.176
0.00272 0.656
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Sample R Q R Q R Q R Q R Q R Q R Q R Q R Q R Q P-value
D 1 S 1 0.0022 0.0019 0.0019 0.0072 0.0010 0.0000 0.0027 0.0002 0.0026 0.0501 0. 355
D 1 S 2 0.0002 0.0083 0.0000 0.0004 0.0001 0.0000 0.0002 0.0000 0.0000 0. 61 6
D1 S3 0.0009 0.0001 0.0000 0.0002 0.0002 0.0004 0.0000 0.0000 0.0000 0.396
D 1 S4 0.0003 0.0001 0.0002 0.0001 0.0012 0.0000 0.0002 0.0006 0.0005 0.0050 0. 364
D 1 S 5 0.0056 0.0008 0.0028 0.0000 0.0025 0.0014 0.0034 0.0013 0.0024 0.0041 0.159
D3S1 0.0938 0.0128 0.0051 0.0213 0.0136 0.0096 0.0054 0.0040 0.0047 0.0032 0.310
D3S2 0.0153 0.0059 0.0001 0.0001 0.0012 0.0001 0.0001 0.0001 0.0000 0.0062 0.934
D3S3 0.0010 0.0008 0.0002 0.0002 0.0042 0.0001 0.0001 0.0012 0.0000 0.0005 0.281
D3S4 0.0161 0.0005 0.0002 0.0003 0.0006 0.0002 0.0002 0.0000 0.0008 0.0005 0.808
D3S5 0.0279 0.0061 0.0141 0.0043 0.0049 0.0102 0.0079 0.0031 0.0046 0.0029 0.488
D7S1 0.0198 0.0100 0.0224 0.0243 0.0116 0.0409 0.0252 0.0142 0.0274 0.0136 0.969
D7S2 0.0137 0.0217 0.0031 0.0026 0.0063 0.0105 0.0141 0.0091 0.0137 0.0019 0.003
D 7 S 3 0.0032 0.0135 0.0040 0.0001 0.0061 0.0114 0.0091 0.0005 0.0003 0.0001 0.049
D7S4 0.0064 0.0097 0.0107 0.0001 0.0035 0.0079 0.0148 0.0047 0.0139 0.0008 0.087
D7S5 0.0116 0.0305 0.0117 0.0084 0.0304 0.0422 0.0596 0.0426 0.0148 0.0061 0.937
D14S1 0.1097 0.0190 0.0120 0.0814 0.0451 0.0341 0.0678 0.0255 0.0247 0.0682 0.102
D14S2 0.0069 0.0167 0.0004 0.0004 0.0040 0.0032 0.0221 0.0020 0.0118 0.0346 0.006
D14S3 0.0075 0.0086 0.0001 0.0001 0.0035 0.0007 0.0138 0.0011 0.0084 0.0054 0.003
D14S4 0.0099 0.0244 0.0000 0.0001 0.0137 0.0010 0.0170 0.0063 0.0199 0.0268 0.002
D14S5 0.0033 0.0203 0.0070 0.0053 0.0582 0.0097 0.0522 0.0533 0.0288 0.0851 0.009
D21S1 0.1039 0.1482 0.1195 0.0453 0.0337 0.691
D21S2 0.0354 0.0381 0.0896 0.0516 0.0039 0.556
D21S3 0.0245 0.0383 0.0230 0.0275 0.0028 0.086
D21S4 0.0228 0.0920 0.0433 0.0815 0.0048 0.337
D21S5 0.1506 0.0243 0.0739 0.2329 0.0871 0.370
D 1 C1 0.0031 0.0004 0.0026 0.0000 0.0004 0.0010 0.0024 0.0000 0.0000 0.0000
D1C2 0.0018 0.0001 0.0008 0.0004 0.0000 0.0000 0.0003 0.0000 0.0000 0.0000
D 1 C 3 0.0001 0.0001 0.0001 0.0000 0.0003 0.0001 0.0001 0.0000 0.0000 0.0000
D 1 C 4 0.0011 0.0003 0.0002 0.0001 0.0000 0.0000 0.0001 0.0000 0.0000 0.0000
D 1 C5 0.0044 0.0015 0.0008 0.0000 0.0007 0.0002 0.0014 0.0000 0.0000 0.0000
D3C1 0.0049 0.0016 0.0117 0.0052 0.0137 0.0050 0.0015 0.0000 0.0060 0.0127
D3C2 0.0043 0.0049 0.0049 0.0028 0.0024 0.0014 0.0008 0.0001 0.0011 0.0014
D3C3 0.0066 0.0001 0.0004 0.0003 0.0031 0.0008 0.0015 0.0005 0.0021 0.0000
D3C4 0.0034 0.0003 0.0005 0.0016 0.0006 0.0025 0.0014 0.0002 0.0048 0.0003
D3C5 0.0078 0.0069 0.0023 0.0020 0.0138 0.0051 0.0066 0.0009 0.0022 0.0026
D7C1 0.1048 0.0053 0.0018 0.0032 0.0148 0.0086 0.0063 0.0275 0.0309 0.0105
D7C2 0.0050 0.0012 0.0016 0.0014 0.0009 0.0026 0.0009 0.0044 0.0058 0.0000
D7C3 0.0010 0.0010 0.0008 0.0015 0.0013 0.0013 0.0006 0.0022 0.0004 0.0040
D7C4 0.0015 0.0017 0.0020 0.0003 0.0024 0.0014 0.0034 0.0013 0.0150
D7C5 0.0178 0.0251 0.0049 0.0015 0.0094 0.0072 0.0086 0.0404 0.0184 0.1147
D14C1 0.1504 0.1093 0.0545 0.1949 0.0656 0.0488 0.0556 0.0307 0.0800 0.0364
D14C2 0.0121 0.0376 0.0544 0.0438 0.0101 0.0357 0.0492 0.1021 0.0247 0.0192
D14C3 0.0109 0.0159 0.0139 0.0107 0.0126 0.0612 0.0653 0.0368 0.0195 0.0309
D14C4 0.0309 0.0283 0.0318 0.0085 0.0533 0.1149 0.0705 0.0472 0.0451 0.1133
D14C5 0.0584 0.0609 0.0743 0.0536 0.0996 0.2316 0.0618 0.0723 0.0745 0.0871
D21C1 0.0394 0.0128 0.0875 0.0622 0.1756
D21C2
D21C3
D21C4
D21C5
Sample R Q R Q R Q
D1S Avg 0.0018 0.0022 0.0010
D3S Avg 0.0308 0.0052 0.0039
D7S Avg 0.0110 0.0171 0.0104
D14S Avg 0.0274 0.0178 0.0039
D21S Avg 0.0000 0.0000 0.0000
D1C Avg 0.0021 0.0005 0.0009
D3C Avg 0.0054 0.0028 0.0040
D7C Avg 0.0321 0.0068 0.0022
D14C Avg 0.0526 0.0504 0.0458
D21C Avg 0.0000 0.0000 0.0000
D1S 1&5 0.0039 0.0014 0.0023
D3S 1&5 0.0608 0.0094 0.0096
D7S 1&5 0.0157 0.0202 0.0170
D14S 1&5 0.0565 0.0196 0.0095
D21S1&5 0.0000 0.0000 0.0000
D1C 1&5 0.0037 0.0010 0.0017
D3C 1&5 0.0064 0.0043 0.0070
D7C 1&5 0.0613 0.0152 0.0034
D14C 1&5 0.1044 0.0851 0.0644
D21C 1&5 0.0000 0.0000 0.0000
D1S 2-4 0.0004 0.0028 0.0001
D3S 2-4 0.0108 0.0024 0.0001
D7S 2-4 0.0078 0.0149 0.0059
D14S 2-4 0.0081 0.0166 0.0001
D21S 2-4 0.0000 0.0000 0.0000
D1C 2-4 0.0010 0.0002 0.0004
D3C 2-4 0.0048 0.0018 0.0019
D7C 2-4 0.0030 0.0013 0.0014
D14C 2-4 0.0180 0.0273 0.0334
D21C 2-4 0.0000 0.0000 0.0000
R Q R Q
0.0016 0.0012
0.0053 0.0049
0.0071 0.0116
0.0175 0.0249
0.0000 0.0000
0.0001 0.0003
0.0024 0.0067
0.0019 0.0053
0.0623 0.0483
0.0000 0.0000
0.0036 0.0018
0.0128 0.0093
0.0164 0.0210
0.0434 0.0516
0.0000 0.0000
0.0000 0.0005
0.0036 0.0138
0.0023 0.0121
0.1243 0.0826
0.0000 0.0000
0.0002 0.0007
0.0002 0.0020
0.0009 0.0053
0.0002 0.0071
0.0000 0.0000
0.0002 0.0001
0.0016 0.0020
0.0016 0.0008
0.0210 0.0254
0.0000 0.0000
0.0179
0.0728
0.0749
0.1196
R Q
0.0004
0.0040
0.0226
0.0098
0.0674
0.0003
0.0029
0.0044
0.0985
0.0649
0.0007
0.0099
0.0415
0.0219
0.1273
0.0006
0.0051
0.0079
0.1402
0.0795
0.0001
0.0001
0.0099
0.0016
0.0275
0.0000
0.0015
0.0021
0.0706
0.0552
0.0304 0.0398 0.1795 0.0510
0.0369 0.0236 0.1475 0.0552
0.0560 0.0144 0.1449 0.0932
0.0670 0.0639 0.0691 0.0711
R Q R Q R Q R Q P-value
0.0013 0.0005 0.0011 0.0118 0.244
0.0027 0.0017 0.0020 0.0027 0.302
0.0246 0.0142 0.0140 0.0045 0.545
0.0346 0.0176 0.0187 0.0440 0.000
0.0682 0.0699 0.0878 0.0265 0.655
0.0008 0.0000 0.0000 0.0000
0.0023 0.0003 0.0032 0.0034
0.0036 0.0156 0.0113 0.0288
0.0605 0.0578 0.0488 0.0574
0.0406 0.0459 0.1206 0.0892
0.0031 0.0007 0.0025 0.0271 0.287
0.0067 0.0036 0.0047 0.0030 0.199
0.0424 0.0284 0.0211 0.0098 0.972
0.0600 0.0394 0.0268 0.0767 0.001
0.0863 0.0967 0.1391 0.0604 0.236
0.0019 0.0000 0.0000 0.0000
0.0040 0.0004 0.0041 0.0076
0.0075 0.0339 0.0246 0.0626
0.0587 0.0515 0.0772 0.0617
0.0399 0.0757 0.0657 0.1234
0.0002 0.0002 0.0017 0.0017 0.178
0.0001 0.0003 0.0024 0.0024 0.833
0.0127 0.0093 0.0010 0.0010 0.023
0.0176 0.0134 0.0223 0.0223 0.000
0.0561 0.0535 0.0038 0.0038 0.074
0.0001 0.0000 0.0000 0.0000
0.0012 0.0027 0.0006 0.0006
0.0010 0.0025 0.0063 0.0063
0.0616 0.0298 0.0545 0.0545
0.0411 0.1573 0.0665 0.0665
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Sample
D1S Avg
D3S Avg
D7S Avg
D14S Avg
D21S Avg
D1C Avg
D3C Avg
D7C Avg
D14C Avg
D21C Avg
D1S 1&5
D3S 1&5
D7S 1&5
D14S 1&5
D21S 1&5
D1C 1&5
D3C 1&5
D7C 1&5
D14C 1&5
D21C 1&5
D1S 2-4
D3S 2-4
D7S 2-4
D14S 2-4
D21S 2-4
D1C 2-4
D3C 2-4
D7C 2-4
D14C 2-4
D21C 2-4
RQ RQ
0.010 0.009
0.227 0.046
0.152 0.330
0.391 0.740
0.000 0.000
0.010 0.003
0.044 0.029
0.131 0.064
0.269 0.324
0.000 0.000
0.026 0.009
0.434 0.086
0.225 0.275
0.794 0.725
0.000 0.000
0.023 0.008
0.056 0.046
0.225 0.111
0.103 0.262
0.000 0.000
0.000 0.009
0.089 0.019
0.104 0.367
0.121 0.749
0.000 0.000
0.002 0.000
0.037 0.018
0.038 0.034
0.379 0.365
0.000 0.000
RQ
0.006
0.018
0.123
0.040
0.000
0.004
0.021
0.052
0.170
0.000
0.014
0.044
0.224
0.098
0.000
0.006
0.048
0.058
0.127
0.000
0.000
0.001
0.055
0.001
0.000
0.002
0.003
0.047
0.198
0.000
D21C2
D21C3
D21C4
D21C5
0.214 0.210 0.378
0.315 0.359 0.551
0.189 0.449 0.381
0.436 0.164 0.178
RQ RQ
0.013 0.006
0.009 0.069
0.123 0.185
0.079 0.416
0.000 0.000
0.002 0.004
0.011 0.015
0.033 0.032
0.186 0.156
0.000 0.000
0.033 0.009
0.020 0.103
0.299 0.250
0.191 0.615
0.000 0.000
0.004 0.011
0.022 0.029
0.036 0.046
0.209 0.106
0.000 0.000
0.000 0.004
0.002 0.046
0.006 0.142
0.004 0.283
0.000 0.000
0.000 0.000
0.004 0.006
0.030 0.022
0.171 0.190
0.000 0.000
0.157 0.238
0.833 0.327
0.953 0.964
0.772 0.727
RQ RQ
0.004 0.014
0.026 0.031
0.092 0.213
0.183 0.660
1.403 1.031
0.004 0.008
0.034 0.035
0.069 0.026
0.399 0.594
0.567 0.459
0.007 0.036
0.066 0.075
0.208 0.316
0.330 0.509
1.962 0.570
0.009 0.019
0.056 0.045
0.057 0.053
0.439 0.331
0.447 0.382
0.000 0.000
0.000 0.002
0.015 0.143
0.085 0.760
1.030 1.338
0.000 0.001
0.020 0.028
0.078 0.008
0.373 0.768
0.647 0.510
RQ RQ RQ P-value
0.005 0.016 0.083 0.218
0.015 0.023 0.019 0.268
0.164 0.337 0.085 0.003
0.184 0.479 0.673 0.395
1.228 1.147 0.841 0.000
0.000 0.000 0.000
0.013 0.024 0.019
0.113 0.072 0.134
0.325 0.284 0.345
0.323 0.259 0.394
0.013 0.034 0.207 0.253
0.035 0.057 0.036 0.164
0.282 0.327 0.199 0.000
0.338 0.391 0.643 0.009
1.416 1.035 0.614 0.020
0.000 0.000 0.000
0.029 0.035 0.030
0.222 0.147 0.184
0.154 0.279 0.239
0.449 0.137 0.329
0.004 0.001 0.001 0.310
0.000 0.007 0.007 0.836
0.344 0.010 0.010 0.123
0.538 0.693 0.693 0.759
1.222 0.992 0.992 0.000
0.000 0.000 0.000
0.017 0.012 0.012
0.022 0.101 0.101
0.288 0.415 0.415
0.339 0.437 0.437
